
# Archives of ALLIED HEALTH SCIENCES

Arch AHS Volume 36 Issue 1 2024





ISSN 2730-2008 (Online)

https://www.tci-thaijo.org/index.php/ams



**The** Archives of Allied Health Sciences (Arch AHS) is an international peer-review multi-disciplinary journal published in English. It is owned by the Faculty of Associated Medical Sciences, Khon Kaen University, Thailand. The Arch AHS was formally known as *Journal of Medical Technology and Physical Therapy (JMTPT)*, which was founded in 1989. The title of the journal was changed to *the Archives of Allied Health Sciences (Arch AHS)* from 2020 (volume 32 issue 2: May - August) onward.

The Arch AHS aims to be a leading forum for research and knowledge in evidence-based practice relating to Allied Health Sciences. Contributions from all parts of the world and from different professionals in Allied Health Sciences are encouraged. Original articles, reviews, special reports, short communications, and letters to the editor are published 3 regular issues per year, online and in print.

#### Editor-in-Chief:

Sugalya Amatachaya, School of Physical Therapy, Khon Kaen University, TH.

#### Associate Editors:

Anchalee Techasen, School of Medical Technology, Khon Kaen University, TH. Thiwabhorn Thaweewannakij, School of Physical Therapy, Khon Kaen University, TH.

#### **Editorial Board Members:**

Neil Robert, Clinical Research and Imaging Centre, University of Edinburgh, UK.
Marco Pang, Department of Rehabilitation Sciences, Hong Kong Polytechnic University, HK.
Michael Hamlin, Department of Sport and Exercise Sciences, Lincoln University, NZ.
Wang Xingze, Research Center in Sport and Exercise Sciences, Gannan Normal University, CN.
Prawit Janwantanakul, Faculty of Allied Health Sciences, Chulalongkorn University, TH.
Eiji Sugihara, Research and Development Center for Precision Medicine, University of Tsukuba, JP.
Charoonsak Somboonporn, Faculty of Medicine, Khon Kaen University, TH.
Wichai Eungpinichpong, Faculty of Associated Medical Sciences, Khon Kaen University, TH.
Cornelis L. Harteveld, Department of Clinical Genetics, Leiden University Medical Center, NL.
Bayden Wood, School of Chemistry, Monash University, AU.

**Production and editorial assistance:** Arpassanan Wiyanad Sirirut Multakorn Gresilia Tambing

All correspondence concerning manuscripts, editorial issues and subscription should be addressed to: Editorial Officer: ArchAHS.TH@gmail.com Faculty of Associated Medical Sciences, Khon Kaen University, Thailand.

#### Publication information:

Arch AHS (ISSN: 2730-1990; eISSN: 2730-2008) appears 3 issues a year. Issue 1 January - April; Issue 2 May - August; Issue 3 September - December.

#### Indexing:

Arch AHS is indexed in Thai Citation Index (TCI tier 1) and ASEAN Citation Index (ACI) databases.

#### Manuscript preparation:

Please review author guideline for manuscript preparation: https://drive.google.com/drive/ folders/1k05FijEnuLSYwzgKcnQ9mx074ZZ0wGRA



Link to website



## Contents

The immediate effects of whole-body vibration on flexibility and ankle systolic blood pressure in middle-aged individuals with type 2 diabetes mellitus May Thandar Khin, Ponlapat Yonglitthipagon, Peeraphat Sripanya, Woramate Chodnok, Kritnapat Wannakarn, Saowanee Nakmaroeng, Wantana Siritaratiwat, Punnee Peungsuwan, Wanida Donpunha	1
Effects of Qigong combined with Muay Thai on cardiorespiratory responses and exercise intensity in sedentary older participants Guang Yang, Narisara Premsri, Terdthai Tong-un, Orathai Tunkamnerdthai, Apiwan Manimmanakorn, Rujira Non-saard, Ploypailin Aneknan, Naruemon Leelayuwat	12
An Excel Visual Basic for Application worksheet for automatic selection of a sigma statistical quality control procedure, facilitating quality management for laboratories <i>Pranadta Wontong</i>	25
Least significant change as an essential tool for monitoring of bone mineral density using dual energy X-ray absorptiometry Thantip Pholwattana, Sirinthorn Sridubdim, Sirinya Nanthanangkul	40

Arch AHS

Archives of Allied Health Sciences 2024; 36(1): 1-11.

### The immediate effects of whole-body vibration on flexibility and ankle systolic blood pressure in middle-aged individuals with type 2 diabetes mellitus

May Thandar Khin, Ponlapat Yonglitthipagon\*, Peeraphat Sripanya, Woramate Chodnok, Kritnapat Wannakarn, Saowanee Nakmaroeng, Wantana Siritaratiwat, Punnee Peungsuwan, Wanida Donpunha

School of Physical Therapy, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen, Thailand.

#### **KEYWORDS**

Vibration exercise; Ankle brachial index; Ankle blood pressure; Diabetes mellitus; Squat exercise.

#### ABSTRACT

Poor body flexibility in middle-aged individuals with type 2 diabetes mellitus (T2DM) could increase the risk of falls and injuries. Insulin resistance induces vascular alterations in the lower extremities, leading to increased ankle systolic blood pressure (SBP), which correlates with an increased risk of cardiovascular disease. The aim of this study was to investigate the acute effects of whole-body vibration (WBV) on flexibility and ankle SBP in middle-aged T2DM patients. This randomized singleblinded crossover design was used to study 14 participants (average age: 49.71  $\pm$  5.28 years, average body mass index: 26.98  $\pm$  3.24 kg/m<sup>2</sup>, average duration of diabetes: 2.32 ± 1.74 years) who were randomly assigned to two intervention sequences, starting with non-whole-body vibration (NWBV) or WBV, with seven participants in each sequence. On days 1 and 8, the intervention varied between NWBV and WBV. The outcomes, including flexibility, ankle blood pressure, brachial blood pressure, and the ankle brachial index, were measured at baseline and 15 min, and 45 min after completing the interventions. A repeated measures two-way ANOVA was used for the data analysis. After a 7-day washout period, neither group exhibited a carryover effect. At the post-intervention period, the WBV intervention resulted in a significant increase in flexibility (+3.52 cm after 15 min and +4.20 cm after 45 min; *p*-value < 0.05) and a significant decrease in ankle SBP (-7.91 mmHg after 15 min; p-value < 0.05) and the ABI (-0.09) after 15 min and -0.07 after 45 min; *p*-value < 0.05). In contrast, the NWBV intervention led to a significant increase in ankle SBP (+10.50 mmHg after 45 min; *p*-value < 0.05). These findings show that middle-aged patients with T2DM might benefit from a single session of 12-min WBV training in terms of improving flexibility, ankle SBP, and the ABI. Therefore, it may be an exercise option for middle-aged T2DM patients.

\*Corresponding author: Ponlapat Yonglitthipagon, PT, PhD. School of Physical Therapy, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen, Thailand. Email address: ponlapat@kku.ac.th

Received: 6 November 2023/ Revised: 28 December 2023/ Accepted: 29 December 2023

#### Introduction

In 2019, Thailand had an estimated 4.8 million adults with type 2 diabetes mellitus (T2DM), and this number is projected to increase to 5.3 million by 2039<sup>(1)</sup>. T2DM typically emerges in middle-aged individuals over the age of  $45^{(2)}$ . It reduces flexibility, especially in overweight or obese individuals, due to decreased mobility and glycation of joint structures, particularly in the lower extremities, significantly impacting overall quality of life<sup>(3)</sup>. Additionally, insulin resistance-induced vascular changes in the lower extremities, evidenced by increased ankle systolic blood pressure (SBP), are linked to cardiovascular disease risk<sup>(4)</sup>. Implementing interventions for middle-aged individuals with T2DM at an early stage of the disease is essential to control blood sugar and prevent irreversible vascular and joint limitations<sup>(5)</sup>.

Aerobic, resistance, and flexibility exercises are effective physical therapy approaches for people with T2DM. However, individuals with T2DM who cannot follow prescribed exercise routines since they are strenuous, time-consuming, and difficult to follow may encounter difficulties in maintaining optimal blood sugar levels<sup>(6)</sup>. Whole-body vibration (WBV) is an innovative fitness practice that involves standing on a platform with electric motors that provide regulated vibrations. This activity has acquired popularity as an alternative or complementary treatment for several health issues, including diabetes<sup>(7)</sup>.

Research has found that a single WBV session led to immediate flexibility improvements in middle-aged individuals with metabolic syndrome and Parkinson's disease, which was attributed to circulatory, thermoregulatory, and neural factors<sup>(8,9)</sup>. However, these studies did not explore the effect of WBV on flexibility beyond the immediate post-WBV period. Another research found that a single WBV session significantly lowered ankle SBP at 30 minutes, but not at 15 minutes, in healthy participants as a result of activating endothelial function, leading to increased nitric oxide production<sup>(10)</sup>. In addition, Figueroa and colleagues found that after 12 weeks of WBV, ankle SBP decreased in post-menopausal women with hypertension<sup>(11)</sup>. However, these studies did not investigate the impact of WBV on ankle SBP at 15 and 45 minutes following the WBV session. Hence, there is a notable gap in evidence regarding the immediate impact of WBV on flexibility and ankle SBP at 15 and 45 minutes after completing the intervention in middle-aged individuals with T2DM. Consequently, the objective of this study was to investigate the immediate effects of WBV on flexibility and ankle SBP in middle-aged patients with T2DM.

#### Materials and methods

#### Study design and participants

This study used a randomized, single-blinded crossover design. The participants were recruited through posters displayed at the village hall in Mueang Khon Kaen District in Khon Kaen, Thailand, between March and July 2023. Figure 1 presents a flowchart of the study enrollment. The sample size calculation was conducted employing the crossover study design formula<sup>(12)</sup> and considered a 2.1 cm change in flexibility following WBV, as observed in a prior study<sup>(8)</sup>. A significant level of alpha of 0.05 and a statistical power of 0.8 were chosen for the two-tailed test, and the total sample size resulted in 11 participants. Given a 10% rate of loss to follow-up, the adjusted total sample size would require 14 participants<sup>(13)</sup>. Therefore, there were 14 middle-aged individuals with T2DM, of which 7 participants were allocated to non-whole-body vibration (NWBV) and 7 participants to WBV in a randomized crossover design using stratified block randomization (block sizes of 4 and 6), with sex as the stratification variable.

The inclusion criteria were as follows: (1) diagnosis with T2DM between 1 and 10 years earlier; (2) age between 40 and 59 years; (3) body mass index (BMI) of  $18.5-29.9 \text{ kg/m}^2$ ; (4) ability to walk without any assistive devices; and (5)

ability to understand and follow the instructions in the research protocol. The exclusion criteria were as follows: (1) brachial blood pressure (BP)  $\geq$  140/90 mmHg; (2) lower extremity pain (visual analog scale > 3) at rest or in a high squat position; (3) regular physical exercise (moderate intensity of  $\geq$  30 min/session  $\geq$  3 sessions/week); (4) musculoskeletal, cardiovascular, or neurological problems; (5) retinopathy and nephropathy; (6) diabetic foot ulcer; (7) tumors or metastases; (8) gall bladder and kidney stones; and (9) pregnant women. This study was carried out at the School of Physical Therapy, Faculty of Associated Medical Sciences, Khon Kaen University, Thailand. The protocol of this study was registered in the Thai Clinical Trial Registry (ID 20230125003) and approved by the Ethics Committee of the Center for Ethics in Human Research, Khon Kaen University (HE652122) and written informed consent was obtained from all participants for this study.




Figure 1 Flowchart of study participants.

#### Interventions

At the beginning of the study, all participants received a 3-minute educational session, and information was provided in a take-home brochure that included a QR code for a video-based education program on T2DM. This session occurred during a 15-minute resting period in the supine position before the initial measurements. The participants were randomized to first receive either NWBV or WBV intervention and after a seven-day washout period<sup>(14)</sup>, they were crossed over to receive the other intervention. The WBV protocol, including frequency, amplitude, and duration was adjusted for participant safety based on previous studies<sup>(10,11,15)</sup> and our own trials. The participants were asked to maintain a static squat position (knees bent at 120°) on a vibrating plate for 1 minute at 25 Hz frequency and 2 mm amplitude. Six sets were performed, with a one-minute rest between sets in a comfortable standing position. Both the WBV and NWBV interventions thus lasted for 12 minutes. This high squat position was employed to reduce vibration transmission to the participant's head, minimizing risks such as vertigo and visual impairment<sup>(16)</sup>. The participants also wore socks to prevent skin irritation. The WBV was administered using a Galileo® S 35 device (Novotec Medical GmbH, Pforzheim, Germany). The NWBV intervention followed the same protocol without the WBV machine being turned on. Before the study began, all participants had the opportunity to become familiar with the equipment and research procedures.



Figure 2 Standing with high squat position on the whole-body vibration machine.

#### **Outcome measures**

The participants were instructed to avoid alcohol and caffeine, not to engage in strenuous physical activity for 24 hours, and refrain from heavy meals for a minimum of 4 hours before the experimental sessions to reduce the possibility of external factors affecting the measurements. A physical therapist with at least five years of clinical experience, who was blinded to the study procedure, sequentially measured brachial and ankle BP and flexibility to minimize confounding factors. The measurements were taken individually before the intervention and at 15 minutes and 45 minutes after the intervention on both days. Each measurement session lasted for 15 minutes, and the participants were required to rest for 15 minutes before each measurement, according to the American Heart Association guideline<sup>(17)</sup>. The room temperature was kept at 25°C, and external stimuli were minimized.

Ankle and brachial BP were measured using a digital sphygmomanometer in the supine position (ICC > 0.9)<sup>(18,19)</sup>. The automatic device's cuff was placed above the ankles<sup>(20)</sup> and on the upper arms<sup>(17)</sup> in a random sequence. The BP readings were taken three times on each side, with a 2minute gap between each measurement. The average of the higher side measurements was used for the statistical analysis.

The sit and reach test was used to assess hamstring and lower back flexibility  $(ICC = 0.92)^{(21)}$ . The participants were seated on the floor without shoes and with their legs extended straight in front of them. They were instructed to slowly lean forward, aiming to reach as far as possible toward a measuring ruler positioned on a box, which ranged from -30 to +30, without bending their knees. Flexibility was measured twice for each participant, and the average of these two measurements was used for the statistical analysis<sup>(21)</sup>.

The ankle brachial inde x was determined through utilization of a formula derived from a prior study<sup>(22)</sup>.

#### Statistical analysis

The data were analyzed using SPSS version 28.0 (SPSS Inc., Chicago, IL, USA). Descriptive statistics were employed to analyze the participants' demographic data. The normality of the data was analyzed using the Shapiro-Wilk test. The parametric test was selected for the data analysis because all the variables were normally distributed. All data are expressed as means and standard deviations. The baseline and post-intervention data within the groups and interventions were compared using a repeated measures two-way ANOVA (*p*-value corrected using the Bonferroni procedure). A *p*-value < 0.05 was considered significant.

#### Results

Table 1 shows the participants' demographic characteristics. Throughout the study duration, neither group exhibited any adverse events, such as nausea, dizziness, hypoglycemia, itching, or skin lesions. Furthermore, no carryover effect was observed, since the baseline values in both groups did not show statistical significance.

Table 1	Demographic	characteristics of th	e participants (n = 14)
---------	-------------	-----------------------	-------------------------

Characteristic	Values [Min-Max]
Age (years)	49.71 ± 5.28 [41-59]
Male/female, n (%)	2 (14.29) / 12 (85.71)
BMI (kg/m²)	26.98 ± 3.24 [19.98-29.94]
Duration of diabetes (years)	2.32 ± 1.74 [1-6]

Note: All values are presented as mean and SD.

Abbreviation: BMI, body mass index; kg/m<sup>2</sup>, kilogram per square meter.

In terms of flexibility, significant time\*group interaction and time effects were observed (p-value < 0.05). Furthermore, significant increases were observed between baseline and both 15 and 45

minutes and between 15 minutes and 45 minutes after the WBV intervention (p-value < 0.05), while the NWBV intervention showed no difference (Table 2).

Ankle SBP showed a significant time\*group interaction and time effects (*p*-value < 0.05). The NWBV intervention showed a significant increase in ankle SBP at 45 minutes after the intervention compared to the baseline. In contrast, the WBV intervention showed a significant decrease from baseline to 15 minutes and a significant increase between 15 minutes and 45 minutes after the intervention (*p*-value < 0.05). Furthermore, at 15 and 45 minutes after the intervention, the WBV intervention showed a statistically significant lower ankle SBP than the NWBV intervention (*p*-value < 0.05), as shown in table 2. Regarding the ABI, time\*group interaction, time, and group effects were significant (*p*-value < 0.05). Compared to the baseline, only the WBV intervention demonstrated significant decreases at 15 and 45 minutes after the intervention (*p*-value < 0.05). Interestingly, at 15 and 45 minutes after the intervention, the WBV intervention had a statistically significant lower ABI than the NWBV intervention (*p*-value < 0.05), as shown in table 2. In contrast, no significant changes from the baseline were observed in ankle diastolic blood pressure (DBP), brachial SBP, and brachial DBP at any time points following between the interventions, as shown in table 2.

<b>Table 2</b> Analysis of the variables between the WBV and NWBV interventions (n = 14)	
ble 2 Analysis of the variables between the WBV and NWBV interventions (n	4
ble 2 Analysis of the variables between the WBV and NWBV interventions (n	
ble 2 Analysis of the variables between the WBV and NWBV ir	Ë
ble 2 Analysis of the variables between the WBV and NWBV ir	=
ble 2 Analysis of the variables between the WBV and NW	' interventions
ble 2 Analysis of the variables between the WBV and NW	ŝ
ble 2 Analysis of the variables between the WBV	₹
ble 2 Analysis of the variables between the WBV	ź
ble 2 Analysis of the variables between the WBV	p
ble 2 Analysis of the variables between the V	ar
ble 2 Analysis of the variables between the V	>
ble 2 Analysis of the variables between the V	ΥB
ble 2 Analysis of the variables between	~
ble 2 Analysis of the variables between	the
ble 2 Analysis of the vari	etween
ble 2 Analysis of the vari	ŝ
ble 2 Analysis of the vari	þ
ble 2 Analys	'arial
ble 2 Analys	>
ble 2 Analys	ĥ
ble 2 Analys	f
ble 2 Analys	0
ble	ysis
ble	Anal
ble	2
	ble

Variables	Group	Baseline (95% Cl)	15 minutes after interventions (95% Cl)	<ul> <li>43 minutes arter</li> <li>interventions</li> <li>(95% Cl)</li> </ul>	Time*group interaction effect	Time effect	Group effect
Flexibility (cm)	NWBV	1.52 ± 5.95 (-1.92 to 4.96)	$1.87 \pm 6.04$ (-1.61 to 5.36)	2.05 ± 5.91 (-1.37 to 5.46)	<i>F</i> (1.45, 37.79) = 46.85	<i>F</i> (1.45, 37.79) = 75.12	F(1, 26) = 1.26
	WBV	1.72 ± 5.91 (-1.69 to 5.14)	5.24 ± 5.71° (1.94 to 8.54)	5.92 ± 5.80° <sup>+</sup> † (2.57 to 9.27)	p < 0.001	<i>p</i> < υ.υυ1 η² = 0.74	<i>p</i> = 0.272 η <sup>2</sup> = 0.05
Ankle SBP (mmHg)	NWBV	146.38 ± 9.70 (140.78 to 151.98)	151.52 ± 13.52 (143.72 to 159.33)	156.88 ± 18.37 <sup>°</sup> (146.28 to 167.49)	F(2, 52) = 10.42	F(2, 52) = 6.03	F(1, 26) = 4.03
	WBV	145.60 ± 10.51 (139.53 to 151.66)	137.69 ± 12.17 *,# (130.66 to 144.72)	$143.26 \pm 14.13^{+, \#}$ (135.11 to 151.42)	p < 0.001	p = 0.004 $n^2 = 0.19$	<i>μ</i> <sup>2</sup> = 0.13
Ankle DBP (mmHg)	NWBV	75.71 ± 6.82 (71.78 to 79.65)	78.60 ± 7.48 (74.28 to 82.92)	78.93 ± 6.69 (75.07 to 82.79)	F(1.56, 40.35) = 0.78	F(1.56, 40.35) = 3.29	F(1, 26) = 1.18
	WBV	74.36 ± 7.39 (70.09 to 78.63)	75.17 ± 7.45 (70.87 to 79.47)	75.62 ± 7.13 (71.50 to 79.73)	p = 0.435 $\eta^2 = 0.03$	ودن. و م ارتخاص 11 م	<i>p</i> = 0.288 η <sup>2</sup> = 0.04
Brachial SBP (mmHg)	NWBV	124.60 ± 7.35 (120.35 to 128.84)	126.81 ± 10.78 (120.58 to 133.04)	128.95 ± 12.08 (121.98 to 135.93)	F(1.58, 41.19) = 0.02	F(1.58, 41.19) = 5.89	F(1, 26) = 0.25
	WBV	122.62 ± 6.57 (118.83 to 126.41)	125.12 ± 9.40 (119.69 to 130.55)	127.55 ± 11.96 (121.98 to 135.93)	$h^2 = 0.00$	μ = υ.υυ <del>ν</del> η² = 0.19	<i>p</i> = 0.624 n <sup>2</sup> = 0.01
Brachial DBP (mmHg)	NWBV	79.88 ± 5.87 (76.49 to 83.27)	83.12 ± 7.23 (78.94 to 87.30)	$81.91 \pm 6.72$ (78.03 to 85.78)	F(2, 52) = 0.69	F(2, 52) = 2.54	F(1, 26) = 2.09
	WBV	77.40 ± 7.20 (73.25 to 81.56)	78.43 ± 6.72 (74.55 to 82.31)	79.21 ± 6.96 (75.20 to 83.23)	$h^2 = 0.03$	μ = υ.υσδ η² = 0.09	p = 0.160 $\eta^2 = 0.08$
ABI	NWBV	1.18 ± 0.06 (1.14 to 1.21)	1.20 ± 0.07 (1.16 to 1.24)	1.22 ± 0.09 (1.17 to 1.27)	F(2, 52) = 10.92	F(2, 52) = 3.66	F(1, 26) = 9.65
	WBV	1.19 ± 0.06 (1.15 to 1.22)	$1.10 \pm 0.05^{\circ, \#}$ (1.07 to 1.13)	1.12 ± 0.05 <sup>°, #</sup> (1.09 to 1.15)	$\eta^2 = 0.30$	μ <sup>2</sup> = 0.12	d = 0.27

vibration; Ankle SBP, ankle systolic blood pressure; Ankle DBP, ankle diastolic blood pressure; Brachial SBP, brachial systolic blood pressure; Note: All values are presented as means and SDs. 'indicates a statistically significant difference within the group compared with the baseline (p-value < 0.05); <sup>†</sup>indicates a statistically significant difference within the group when comparing 15 minutes to 45 minutes Abbreviation: 95% Cl, 95% confidence interval; F, F-test; n<sup>2</sup>, partial eta square; WBV, whole-body vibration; NWBV, non-whole-body (*p*-value < 0.05); "indicates a statistically significant difference between the groups (*p*-value < 0.05).

Brachial DBP, brachial diastolic blood pressure; ABI, ankle brachial index.

#### Discussion

This study aimed to examine the acute effects of WBV on flexibility and ankle SBP in middle-aged individuals with T2DM. The results showed that the WBV intervention significantly increased flexibility and decreased ankle SBP and the ABI. The higher number of female participants might be attributed to increased insulin resistance and decreased estrogen levels following menopause in the 49-51-year-old age group<sup>(23)</sup>. The participants, with a mean BMI of 26.98 kg/m<sup>2</sup>, were overweight and at increased risk of diabetes<sup>(24)</sup>. Additionally, our study did not show significant carryover effects for any variables, indicating that the washout duration was adequate.

Flexibility improved from "fair" to "good"<sup>(25)</sup> at different time points: 15 minutes (+3.52 cm) and 45 minutes (+4.20 cm) post-WBV compared to the baseline, indicating a lasting positive effect for at least 45 minutes after a single WBV session. Similar findings have been observed in elderly people with Parkinson's disease, in whom flexibility increased by 3.86 cm immediately after WBV<sup>(9)</sup>. Another study showed that middle-aged healthy females had a 3.6 cm flexibility improvement following two months of WBV<sup>(26)</sup>. A 2.5 cm improvement in the sit and reach test is considered clinically meaningful<sup>(27)</sup>. A single WBV session likely increases flexibility by enhancing stretch reflex sensitivity through la inhibitory neurons, altering muscle activity patterns, reducing braking forces, and decreasing muscle stiffness<sup>(9)</sup>. WBV also stimulates Golgi tendon organs via the lb pathway, inducing muscle relaxation and inhibiting contractions<sup>(9)</sup>. Improved blood circulation, thermoregulation, and neural mechanisms during WBV contribute to enhanced flexibility by increasing vasodilation, elevating blood flow and muscle temperature, reducing tissue thickness, and promoting muscle elasticity while minimizing discomfort<sup>(28)</sup>.

The current findings revealed a significant 7.91 mmHg reduction in ankle SBP at 15 minutes compared to the baseline, remaining within the normal range. This indicates that the acute effect of a single WBV session on ankle SBP persisted for a minimum of 15 minutes. Previous research has also demonstrated a decrease in ankle SBP by 9.8 mmHg in healthy adults after 30 minutes of a single WBV session<sup>(10)</sup>. Another study reported a 6.68 mmHg decrease in ankle SBP after 50 heel raises in a standing position among healthy elderly individuals<sup>(29)</sup>. Furthermore, a more substantial 24 mmHg reduction in ankle SBP was observed in postmenopausal women with high baseline ankle SBP ( $\geq$  175 mmHg) after 12 weeks of WBV, likely due to the longer training duration and higher initial SBP levels of participants<sup>(11)</sup>.

A previous study has suggested that a reduction in ankle SBP exceeding 30 mmHg post-treadmill exercise indicates peripheral arterial disease<sup>(30)</sup>. However, our participants, with an average diabetes duration of 2.32 years, might not have progressed to that PAD stage<sup>(31)</sup>. WBV exercise in a high squat position enhances lower limb muscle activation, relaxing vascular smooth muscles, reducing arterial stiffness, and promoting local vasodilation through nitric oxide production, thus lowering ankle SBP<sup>(10)</sup>. Conversely, a NWBV intervention increases ankle SBP due to muscle contractions during static high squat exercises performed without WBV, constraining blood capillaries and obstructing circulation<sup>(32)</sup>.

In this study, significant ABI reductions were observed post-WBV intervention: a 7.56% decrease at 15 minutes and 5.88% at 45 minutes, which all remained within the normal range. This finding suggests that the effect of a single session of WBV on the ABI persists for at least 45 minutes. Figueroa and colleagues observed a 3.85% reduction in the ABI after 12 weeks of WBV in postmenopausal women with increased ankle SBP<sup>(11)</sup>. Another study reported a 9.62% ABI reduction after 50 heel raises in a standing position for healthy elderly people<sup>(29)</sup>. Our findings align with research indicating a 5% reduction in the ABI following a single exercise session in healthy individuals<sup>(33)</sup>. In this study, the observed ABI reduction may be attributed to the following mechanisms: 1) increased central aortic pressure and decreased peripheral BP at the ankles during exercise, delivering more oxygenated blood to meet leg muscle metabolic demands, leading to a small reduction in the ABI, and 2) high shear stress, such as during WBV exercise, triggering endothelial substance release and vasodilation<sup>(10)</sup>. This study observed non-significant increases in ankle DBP, brachial SBP, and brachial DBP after both interventions, indicating that the increased parameters were within the normal range according to American Heart Association standards<sup>(34)</sup>. Previous studies found that a single WBV session did not result in significant decreases in ankle DBP or brachial SBP or DBP in healthy young adults<sup>(10)</sup> and adults with obesity<sup>(35)</sup>. Another study found that a high squat position reduced vibration transmission to the upper extremities, resulting in insignificant vasodilation<sup>(36)</sup>. Holding the WBV machine handles to maintain this position during both interventions also caused a pressor rise in brachial BP, which is vital for muscle perfusion during prolonged contraction<sup>(37)</sup>.

Regarding limitations, the findings of our study may not be generalizable to different populations, such as obese individuals with T2DM. Future research should include individuals with T2DM across various age groups, especially those with longer diabetes duration (> 10 years) and higher ankle SBP (>175 mmHg), with a focus on potential clinically significant improvements. Furthermore, our study did not extend its assessment of the acute effects of WBV beyond the 45-minute recovery period. Thus, future research should investigate the effects of WBV over longer durations. Additionally, relying solely on the sit and reach test may be insufficient for accurately evaluating changes in lower extremity flexibility. Despite these limitations, the strength of our study lies in its use of a crossover design, which allowed for a more comprehensive evaluation of treatment impact by comparing outcomes within each participant, thus mitigating individual differences, and potentially reducing the influence of covariates.

#### Conclusions

A single 25 Hz, 2 mm, 12-minute WBV session can significantly enhance flexibility and lower ankle SBP and the ABI in middle-aged T2DM patients without any adverse effects or complications.

#### Take home messages

WBV offers a safe and promising alternative exercise method with the potential to mitigate cardiovascular risk in middle-aged individuals with T2DM. Nevertheless, it is crucial to exercise caution, especially for those with hypertension, as the high squat exercise without WBV can raise both brachial and ankle BP levels.

#### **Conflicts of interest**

The authors declare no conflict of interest.

#### Acknowledgments

The authors would like to thank all participants who contributed to this study. This research was supported by the Khon Kean University Scholarship for ASEAN and GMS Countries.

#### References

- Apidechkul T, Chomchoei C, Upala P. Epidemiology of undiagnosed type 2 diabetes mellitus among hill tribe adults in Thailand. Sci Rep 2022; 12(1): 3969.
- Kaleru T, Vankeshwaram VK, Maheshwary A, Mohite D, Khan S, Vankeshwaram V. Diabetes mellitus in the middle-aged and elderly population (> 45 years) and its association with pancreatic cancer: an updated review. Cureus 2020; 12(6).
- Paiva PC, Figueiredo CA, Reis-Silva A, Francisca-Santos A, Paineiras-Domingos LL, Martins-Anjos E, et al. Acute and cumulative effects with whole-body vibration exercises using 2 biomechanical conditions on the

- Viswambharan H, Cheng CW, Kain K. Differential associations of ankle and brachial blood pressures with diabetes and cardiovascular diseases: Cross-sectional study. Sci Rep 2021; 11(1): 9406.
- 5. Liu R, Li L, Shao C, Cai H, Wang Z. The impact of diabetes on vascular disease: Progress from the perspective of epidemics and treatments. J Diabetes Res 2022; 2022.
- Unick JL, Jakicic JM, Marcus BH. Contribution of behavior intervention components to 24-month weight loss. Med Sci Sports Exerc 2010; 42(4): 745-53.
- Baum K, Votteler T, Schiab J. Efficiency of vibration exercise for glycemic control in type 2 diabetes patients. Int J Med Sci 2007; 4(3): 159-63.
- Sá-Caputo DC, Paineiras-Domingos LL, Oliveira R, Neves MF, Brandão A, Marin PJ, et al. Acute effects of whole-body vibration on the pain level, flexibility, and cardiovascular responses in individuals with metabolic syndrome. Dose-Response 2018; 16(4).
- 9. Dincher A, Becker P, Wydra G. Effect of whole-body vibration on freezing and flexibility in Parkinson's disease-a pilot study. Neurol Sci 2021; 42(7): 2795-801.
- 10. Kim E, Okamoto T, Song J, Lee K. The acute effects of different frequencies of whole-body vibration on arterial stiffness. Clin Exp Hypertens 2020; 42(4): 345-51.
- 11. Figueroa A, Kalfon R, Wong A. Whole-body vibration training decreases ankle systolic blood pressure and leg arterial stiffness in obese postmenopausal women with high blood pressure. Menopause 2015; 22(4): 423-7.
- Sawangjaithum K, Khrongkab N, Hancharoenkul B, Vimolratana O, Champrug K. The immediate effects of ankle dorsiflexor electrical stimulation on gait in patients with chronic hemiplegia. ASEAN J Rehabil Med 2018; 28(3): 94-100.

- 13. Pitiphat W. Research methodology in dentistry. Khon Kaen: Khon Kaen University; 2014.
- 14. Tsuji T, Kitano N, Tsunoda K, Himori E, Okura T, Tanaka K. Short-term effects of whole-body vibration on functional mobility and flexibility in healthy, older adults: a randomized crossover study. J Geriatr Phys Ther 2014; 37(2): 58-64.
- 15. Gerodimos V, Zafeiridis A, Karatrantou K, Vasilopoulou T, Chanou K, Pispirikou E. The acute effects of different whole-body vibration amplitudes and frequencies on flexibility and vertical jumping performance. J Sci Med Sport 2010; 13(4): 438-43.
- Chuang LR, Yang WW, Chang PL, Chen VC, Liu C, Shiang TY. Managing vibration training safety by using knee flexion angle and rating perceived exertion. Sensors (Basel). 2021; 21(4).
- 17. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, et al. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: Blood pressure measurement in humans - a statement for professionals from the subcommittee of professional and public education of the American Heart Association Council on high blood pressure research. Circulation 2005; 111(5): 697-716.
- Barrios-Fernandez S, Sosa-Sánchez EM, Carlos-Vivas J, Muñoz-Bermejo L, Morenas -Martín J, Apolo-Arenas MD, et al. Intrasession reliability analysis for oscillometric blood pressure method using a digital blood pressure monitor in peruvian population. Healthcare (Basel) 2022; 10(2).
- Cao X, Song C, Guo L, Yang J, Deng S, Xu Y, et al. Quality control and validation of oscillometric blood pressure measurements taken during an epidemiological investigation. Medicine (Baltimore) 2015; 94(37).
- Aboyans V, Criqui MH, Abraham P, Allison MA, Creager MA, Diehm C, et al. Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association. Circulation 2012; 126(24): 2890-909.

- 21. Ayala F, de Baranda PS, Croix MD, Santonja F. Reproducibility and criterion-related validity of the sit and reach test and toe touch test for estimating hamstring flexibility in recreationally active young adults. Phys Ther Sport 2012; 13(4): 219-26.
- 22. Benchimol D, Pillois X, Benchimol A, Houitte A, Sagardiluz P, Tortelier L, et al. Accuracy of ankle-brachial index using an automatic blood pressure device to detect peripheral artery disease in preventive medicine. Arch Cardiovasc Dis 2009; 102(6-7): 519-24.
- Ciarambino T, Crispino P, Leto G, Mastrolorenzo E, Para O, Giordano M. Influence of gender in diabetes mellitus and its complication. Int J Mol Sci 2022; 23(16).
- 24. Ruze R, Liu T, Zou X, Song J, Chen Y, Xu R, et al. Obesity and type 2 diabetes mellitus: Connections in epidemiology, pathogenesis, and treatments. Front Endocrinol 2023; 14.
- 25. Sport FJO, Ont. Canadian standardized test of fitness: Operations manual 1986.
- Gerodimos V, Zafeiridis A, Chanou K, Karatrantou K, Dipla K. Whole-body vibration training in middle-aged females: Improving muscle flexibility and the power of lower limbs. Sport Sci Health 2015; 11: 287-94.
- 27. Williams W, Selkow NM. Self-myofascial release of the superficial back line improves sit-and-reach distance. J Sport Rehabil 2020; 29(4): 400-4.
- Shirato R, Sakamoto H, Sugiyama T, Suzuki M, Takahashi R, Tanaka T. Inhibitory effects of prolonged vibratory stimulus on the maximal voluntary contraction force and muscle activity of the triceps brachii: An experimental study. J Chiropr Med 2019; 18(2): 97-105.
- 29. Alqahtani KM, Bhangoo M, Vaida F, Denenberg JO, Allison MA, Criqui MH. Predictors of change in the ankle brachial index with exercise. Eur J Vasc Endovasc Surg 2018; 55(3): 399-404.

- Laing S, Greenhalgh RM. The detection and progression of asymptomatic peripheral arterial disease. Br J Surg 1983; 70(10): 628-30.
- 31. Chen YW, Wang YY, Zhao D, Yu CG, Xin Z, Cao X, et al. High prevalence of lower extremity pe ripheral artery disease in type 2 diabetes patients with proliferative diabetic retinopathy. PLoS One 2015; 10(3).
- Hietanen E. Cardiovascular responses to static exercise. Scand J Work Environ Health 1984; 10(6 Spec No): 397-402.
- Ouriel K, McDonnell AE, Metz CE, Zarins CK. Critical evaluation of stress testing in the diagnosis of peripheral vascular disease. Surgery 1982; 91(6): 686-93.
- 34. Whelton PK, Carey RM, Mancia G, Kreutz R, Bundy JD, Williams B. Harmonization of the American college of cardiology/American heart association and European society of cardiology /European society of hypertension blood pressure/hypertension guidelines: Comparisons, reflections, and recommendations. Eur Heart J 2022; 43(35): 3302-11.
- 35. Tamini S, De Micheli R, Tringali G, Bernardo -Filho M, Sartorio A. Acute effects of whole -body vibration exercises at 2 different frequencies versus an aerobic exercise on some cardiovascular, neuromotor and musculoskeletal parameters in adult patients with obesity. Dose-Response 2020; 18(4).
- 36. Figueroa A, Gil R, Sanchez-Gonzalez MA. Whole-body vibration attenuates the increase in leg arterial stiffness and aortic systolic blood pressure during post-exercise muscle ischemia. Eur J Appl Physiol 2011; 111(7): 1261-8.
- Hanson P, Nagle F. Isometric exercise: Cardiovascular responses in normal and cardiac populations. Cardiol Clin 1987; 5(2): 157-70.



Archives of Allied Health Sciences 2024; 36(1): 12-22.

# Effects of Qigong combined with Muay Thai on cardiorespiratory responses and exercise intensity in sedentary older participants

Guang Yang<sup>1,2,3</sup>, Narisara Premsri<sup>1,2</sup>, Terdthai Tong-un<sup>2,4</sup>, Orathai Tunkamnerdthai<sup>2,4</sup>, Apiwan Manimmanakorn<sup>2,4</sup>, Rujira Nonsa-ard<sup>5</sup>, Ploypailin Aneknan<sup>2</sup>, Naruemon Leelayuwat<sup>1,2,\*</sup>

<sup>1</sup> Exercise and Sport Sciences Program, Graduate School, Khon Kaen University, Khon Kaen, Thailand.

<sup>2</sup> Exercise and Sport Sciences Development and Research Group, Khon Kaen University, Khon Kaen, Thailand.

<sup>3</sup> Faculty of Physical Education, Henan institute of economics and trade, Zhengzhou, China.

<sup>4</sup>Department of Physiology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.

<sup>5</sup> Faculty of Public Health, Mahasarakham University, Mahasarakham, Thailand.

#### **KEYWORDS**

Exercise; Ventilation; Endurance; Physical activity; Aging.

#### ABSTRACT

Khon Kaen Qigong (KKQ) is a new type of exercise that combines Qigong (Baduanjin and Wuqinxi) with Muay Thai. No studies have demonstrated its effects on exercise intensity and cardiorespiratory responses. We aimed to investigate the intensity of the exercise using the cardiorespiratory responses in sedentary older adults. This was a randomized, controlled, pre-and post-test parallel-group study. The participants were randomly assigned to one of the two groups (n=30 each): the exercise or the control group. There were three phases (30 min each) for each activity, including before (baseline), during, and after (recovery) reading a book in the control group or performing KKQ in the exercise group. Heart rate and blood pressure were measured before, immediately after, and 30-min after the activities. Expired gas was collected to measure the respiratory responses and ventilatory efficiency throughout the experiment. Compared with reading, KKQ increased heart rate (p-value < 0.05) and respiratory responses and decreased ventilatory efficiency (All were p-value < 0.01). Markers indicating exercise intensity indicated very low-intensity exercises. This study suggests that a single bout of KKQ can be classified as a very light-intensity exercise according to very low increased cardiorespiratory responses in sedentary older participants. It also decreases ventilatory efficiency, which is related to cardiovascular risk factors. Further studies on KKQ training may confirm its impact on cardiovascular disease interventions.

<sup>\*</sup>Corresponding author: Naruemon Leelayuwat, PhD. Exercise and Sport Sciences Program, Graduate School, Khon Kaen University, Khon Kaen, Thailand. Email address: naruemon@kku.ac.th; naruemon.leelayuwat@gmail.com Received: 19 October 2023/ Revised: 24 December 2023/ Accepted: 28 December 2023

#### Introduction

The world's population is aging; the number of older people aged  $\geq$ 60 years will soon exceed the younger population, and the proportion of older people will reach 21% by 2050<sup>(1)</sup>. Aging leads to an increased incidence of cardiorespiratory disease, as well as increases in morbidity and mortality<sup>(2,3)</sup>. Therefore, exploring interventions to prevent these diseases is crucial to promote the health of older adults. Exercise-based rehabilitation programs prevent comorbidities and decrease mortality<sup>(4,5)</sup>.

We invented a novel exercise called Khon Kaen Qigong (KKQ) for sedentary older adults. This could be an interesting choice for them because it is modified from two popular cultural exercises: traditional Qigong (Baduanjin and Wuqinxi) and Muay Thai (Wai Khru session)<sup>(6)</sup>. Both Qigong types are the most widely practiced types of traditional Chinese Qigong, which are mind-body exercises, whereas Wai Khru is a pre-session of Muay Thai, the most popular martial sport in Thailand<sup>(7-9)</sup>.

Both Qigong and Wai Khru provide meditation and gentle and smooth movements, which are appropriate for the older population<sup>(7-10)</sup>. Taken together, the popularity and modified beautiful movements of the KKQ may motivate older people to adhere to KKQ practice. Our previous study demonstrated that acute KKQ in sedentary older adults led to sympathetic dominance, as evidenced by increasing heart rate (HR) and respiratory rate (RR)<sup>(6)</sup>. However, this previous study was a pilot trial requiring further investigation with more participants and cardiorespiratory variables to explore more knowledge of acute KKQ before exploring the training effect.

Exercise intensity is an important component of exercise prescriptions. This is indicated by cardiorespiratory responses. Literature reporting the responses to each component of KKQ documented that only one study was done investigating Baduanjin in older participants and found an acute increase in oxygen consumption (VO<sub>2</sub>) and a moderately increased HR<sup>(11)</sup>. However, the participants were patients with chronic heart failure and cardiac dysfunction, and their hearts worked harder than those of healthy people as shown in the report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines<sup>(12)</sup>. Thus, healthy older adults without heart disease may yield different results. Data on the effect of the KKQ and its components on exercise intensity as indicated by cardiorespiratory variables in healthy, sedentary older people are not yet available.

Therefore, this study aimed to determine the intensity of the KKQ and its single-session effects on cardiorespiratory variables in sedentary older adults. For the response to a single bout of KKQ, we chose reading a book as the control activity because a 30-min reading was reported to have no stimulation on the cardiopulmonary responses<sup>(6)</sup>. Thus, compared to reading, the effect of a single bout of KKQ on the cardiopulmonary responses should be clearly observed. We hypothesized that a single bout of KKQ is a low-intensity exercise, as indicated by the low response of the cardiorespiratory system in sedentary older participants.

#### Materials and methods

#### **Participants**

This study was conducted from June 2021 to February 2022 in the Khon Kaen Province, Thailand. Participants aged 60-75 years were recruited. Participants received verbal and written explanations before signing the consent form. They were screened through body composition, anthropometry, physical examinations, electrocardiography, blood chemistry, baroreceptor reflex, and questionnaires for health status and readiness to exercise (using the Physical Activity Readiness Questionnaire, PAR-Q). Participants who had no kidney, liver, or cardiac disease, obesity, and exercise limitation were recruited. Moreover, those who had no regular (longer than 1 hour/week) long-term (>2 years) experience with meditation, Qigong, or other types of exercise were included. However, participants with these diseases or chronic infection were excluded. Ethical approval was obtained from the Ethics Committee of Khon Kaen University (HE641163).

Sample size calculation was calculated by G\*Power 3.1 (Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany) based on a previous study<sup>(11)</sup> of the therapeutic effect of Qigong on the VO<sub>2</sub> with effect size of 0.53, a power of 80%, and an alpha of 5%. The sample size in each group was 30 (including a dropout rate of 20%).

## Research design, randomized allocation, and blinding

This was a randomized, controlled, preand post-test, study. To maintain and guarantee blinding, the outcome adjudicators and data analysts were blinded by using participants' code. However, participants and the researcher who collected gas sample were not blinded because both knew the intervention. Nonetheless, participants were blinded to group allocation. The randomized allocation sequence (1:1) was performed using computer-generated random numbers and kept in sequentially numbered, opaque, sealed envelopes. However, a researcher who gave an envelope to the participant for group allocation is not the one who prepared the envelope.

#### Protocols

Participants who passed the screening were randomly allocated to one of the two groups (n=30 each): the KKQ group (KKG) and the control group (CG).

The KKG visited the laboratory three times at 8:00 am after an overnight fast. During the first visit, they performed the KKQ (Supplementary Figure S1)<sup>(6)</sup> for 30 min to familiarize themselves with the exercise. Two days later, they visited the laboratory to collect the expired gases during three phases (30 min each), including resting in a supine position before (baseline), during and after KKQ (recovery in supine position), to measure RR, ventilation rate ( $V_E$ ), VO<sub>2</sub>, and carbon dioxide production rate (VCO<sub>2</sub>). HR, BP, rating of perceived exertion (RPE), and dyspnea (RPD) were recorded immediately before and at the end of the KKQ and recovery. The room temperature and humidity were recorded throughout the experiment. Two days later, they again came to the laboratory to measure peak VO<sub>2</sub> (VO<sub>2,peak</sub>) by 6-min walk test (6MWT)<sup>(13)</sup>.

The CG participated during a single visit. They performed the same experimental procedure as during the second visit to the KKG, except that the KKQ was replaced by reading a Dhamma book while sitting. The Dhamma book was the same for all participants in this group.

Participants' measurements of all anthropometry, body composition, and cardiovascular outcomes were assessed as described in a previous study<sup>(14)</sup>. Furthermore, all respiratory outcomes were collected and analyzed with a gas analyzer (Oxycon CareFusion 234 GmbH, Höchberg, Germany). Then percentage of maximal HR (%HRmax) and VO<sub>2,peak</sub> (%VO<sub>2,peak</sub>), RPE<sup>(15)</sup>, and RPD<sup>(16)</sup> were used to indicate exercise intensity. In addition, V<sub>E</sub>, VO<sub>2</sub>, and VCO<sub>2</sub> were used to calculate ventilatory efficiency<sup>(17)</sup>.

#### Statistical analysis

All statistical analyses were performed using SPSS version 26.0 (IBM, Armonk, NY, USA). The Kolmogorov-Smirnov test was used to test the normality of the data. The independent t-test was used to compare continuous variables of characteristics with a normal distribution between groups. Repeated-measures ANOVA was used to compare continuous variables with a normal distribution within and between groups. The Bonferroni test was used as a post hoc test. The Mann-Whitney U test was used for ordinal data or unpaired samples that were not normally distributed. A p-value of < 0.05 was considered statistically significant. Results were expressed as mean ± standard deviation (SD) or stated elsewhere.

#### Results

Of the 90 eligible participants, 66 were included in this study (Supplementary Figure S2). The remaining participants were unable to participate because they did not meet the inclusion criteria (n=10), declined to participate (n=10), or for other reasons (n=4). They were then randomly allocated to one of the two groups: the KKG or the CG (n= 33 each). Thirty participants (28 females and two males in each group) completed

the experiment. In the KKG, two female participants left the study for family reasons, and one male participant dropped out due to physical discomfort. In the CG, three female participants dropped out of the study for physical reasons. The room temperature and humidity were  $24.9\pm0.9^{\circ}$ C and  $59.4\pm4.7\%$ . There were no significant differences in all characteristics and cardiorespiratory outcomes between groups at baseline (Table 1, Figure 1-3).

Table 1
 Baseline demography, anthropometry, body composition, hemodynamics, and blood chemistry of participants in both groups

	CG (n=30)	KKG (n=30)
Age (yr) <sup>a</sup>	68±4.6	70±6.04
Sex (male/female)	2/28	2/28
BM (kg) <sup>a</sup>	57.2±9.47	58.8±8.82
BMI (kg/m²)ª	24.6±3.54	25.5±3.05
W (cm) <sup>a</sup>	85.5±12.15	87.7±8.65
H (cm) <sup>a</sup>	98.3±7.35	99.3±6.47
W/H <sup>a</sup>	0.89±0.06	0.87±0.06
BF (%) <sup>a</sup>	33.6±4.98	35.2±4.05
FM (kg)ª	19.1±5.8	21.1±4.3
LBM (kg) <sup>a</sup>	35.9±8.8	36.9±6.2
HR (/min)ª	74.6±11.3	70.9±8.3
SBP (mmHg)ª	132.5±15.8	125.9±14.4
DBP (mmHg)ª	79.4±11.7	72.1±8.9
MAP (mmHg) <sup>a</sup>	98.1±13.9	87.1±12.8
FBG (mg/dL) <sup>a</sup>	112.6±37.2	104.1±31.4
TC (mg/dL) <sup>a</sup>	212.2±35.2	227.9±47.2
TG (mg/dL) <sup>a</sup>	151.6±78.0	148.6±91.4
HDL-c (mg/dL)ª	51.3±17.4	50.4±14.0
LDL-c (mg/dL)ª	136.1±34.6	151.5±43.7
Cr (mg/dL)ª	0.84±0.18	0.83±0.12
SGPT (U/L) <sup>a</sup>	19.3±18.6	15.2±5.79

**Note:** The data are presented by mean  $\pm$  SD. <sup>a</sup>The independent t-test was used to compare continuous variables with normal distribution between groups.


Abbreviation: BM, body mass; BMI, body mass index; W, waist circumference; H, hip circumference; BF, body fat; FM, fat mass; LBM, lean body mass; FBG, fasting blood glucose; TC, total cholesterol; TG, triacylglycerol; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; Cr, creatinine; SGPT, serum glutamate pyruvate transaminase.

#### Cardiovascular outcomes

#### HR

Compared with baseline, HR significantly increased immediately after KKQ and reading and

recovery, with a greater value immediately after KKQ compared with reading (All were p-value < 0.05) (Figure 1A).



**Figure 1** (A) Heart rate (/min), (B) Systolic blood pressure (mmHg), (C) Diastolic blood pressure (mmHg), and (D) Mean arterial pressure (mmHg) at baseline, immediately after KKQ/Reading, and at the end of recovery.

**Note:** Data are presented as mean±SE (n=30 each group). \* within the group (*p*-value < 0.05); # between groups (*p*-value < 0.05).

Abbreviation: CG, control group; KKG, Khon Kaen Qigong group.

#### BP

Compared to baseline, SBP significantly increased immediately after KKQ and recovery (Both were *p*-value < 0.05) in the KKG (Figure 1B), but no changes were found in the CG. No significant differences in SBP were observed between the groups. Furthermore, no significant differences in DBP and MAP were found within or between the groups (Figure 1C and 1D).

#### Respiratory outcomes

#### RR

Compared with the baseline, the RR was significantly increased from 10 to 30 min during KKQ, with greater values in the KKG than in the CG for 20-30 min (All were *p*-value < 0.01) (Figure 2A). Furthermore, the RR was greater than baseline at 5- and 15-min during recovery from KKQ. The RR decreased during the KKQ throughout

recovery and returned to baseline during the last 10 min (All were *p*-value < 0.01). However, there were no significant changes in RR throughout the experiment in the CG.


 $V_E$ Compared with baseline and CG,  $V_E$  were significantly greater throughout the KKQ (5-30 min) (All were *p*-value < 0.01) (Figure 2B). Then, the KKG had decreased  $V_E$  from during KKQ throughout recovery and returned to baseline during the last 10 min of recovery (All were *p*-value < 0.01).  $V_E$  was significantly greater during KKQ than reading at 5-10 min (*p*-value < 0.05) of recovery.  $V_E$  did not change throughout the entire experiment in the CG.

#### VO,

Compared with baseline and the CG, VO<sub>2</sub> was significantly greater throughout the KKQ (5-30 min) until 5 min into recovery (All were *p*-value < 0.01) (Figure 2C). The KKG had a lower VO<sub>2</sub> during recovery than during KKQ (*p*-value < 0.01) and returned to baseline during the last 25 min of recovery. VO<sub>2</sub> did not change throughout the entire experiment in the CG.

#### VCO<sub>2</sub>

Changes of VCO<sub>2</sub> were the same as those of VO<sub>2</sub>, except the KKG had a greater VCO<sub>2</sub> than baseline 15 min into recovery (All were *p*-value < 0.05). VCO<sub>2</sub> did not change throughout the entire experiment in the CG (Figure 2D).



**Figure 2** (A) Respiratory rate (breaths/min), (B) ventilation rate (L/min), (C) Oxygen consumption rate (mL/min), (D) Carbon dioxide production rate (mL/min) at baseline, during KKQ/Reading, and recovery in both groups.

**Note:** Data are presented as mean $\pm$ SE (n=30 each group). \*,\*\* Different from baseline within the group (*p*-value < 0.05, 0.01), <sup>SS</sup> different from that during the KKQ within the KKG (*p*-value < 0.01), <sup>#,##</sup> different between groups at the same time point (*p*-value < 0.05, 0.01).


Abbreviation: CG, control group; KKG, Khon Kaen Qigong group.

#### $V_{E}/VO_{2}$

Compared with baseline,  $V_E/VO_2$  was significantly decreased during KKQ (5-25 min) (All were *p*-value < 0.01 except at 25 min (*p*-value < 0.05)) and increased at 10 min into recovery (*p*-value < 0.01) (Figure 3A). Compared with the CG,  $V_E/VO_2$  in the KKG was significantly lower at 10 min during KKQ (*p*-value < 0.01) and greater at 5-20 min into recovery (All were *p*-value < 0.01). In the KKG,  $V_E/VO_2$  during recovery was greater than during KKQ (All were *p*-value < 0.01).  $V_E/VO_2$  did not change throughout the entire experiment in the CG.

#### $V_{E}/VCO_{2}$

Compared with baseline and the CG,  $V_{e}/VCO_{2}$  was significantly lower throughout KKQ (5-25 min) (All were *p*-value < 0.01, except at 5 min compared with CG (*p*-value < 0.05) (Figure 3B).  $V_{e}/VCO_{2}$  of the KKG returned to baseline at 25 min of KKQ until the end of recovery.  $V_{e}/VCO_{2}$ did not change throughout the entire experiment in the CG.



**Figure 3** Ventilatory efficiency at baseline, during KKQ/Reading, and recovery in both groups. Data are presented as mean±SE (n=30 each group).

**Note:** \*,\*\*Different from baseline within the group (*p*-value < 0.05, 0.01), <sup>\$\$</sup> different from that during the KKQ within the KKG (*p*-value <0.01), <sup>#,##</sup> different between groups at the same time point (*p*-value < 0.05, 0.01).

**Abbreviation:** CG, control group; KKG, Khon Kaen Qigong group;  $V_E/VO_2$ , ventilatory efficiency relative to  $VO_2$ ;  $V_E/VCO_2$ , ventilatory efficiency relative to  $VCO_2$ .

#### Intensity of exercise<sup>(16,18)</sup>

%HRmax indicated that KKQ was a very light-intensity exercise (Table 1). Furthermore, the VO<sub>2,peak</sub> of the participants in KKG was  $32.2\pm4.34$  mL/kgBM/min. The %VO<sub>2,peak</sub> determined that KKQ was a very light-intensity exercise. The

highest %VO<sub>2,peak</sub> was during the first round of KKQ (Supplementary Figure S3). The RPE and RPD also increased to a very light to light level of exertion during the KKQ. No participants complained of any discomfort or injury from KKQ.

Table 2 Exercis	e intensity of KKQ	of participants
-----------------	--------------------	-----------------

Variable	Mean±SD	Reference values	Exercise intensity
%HRmax	54.1±9.5	<57	Very-light
%VO <sub>2,peak</sub>	20.9±5.0	<37	Very-light
Rating of perceived exertion	10.6±1.8	9-11	Very light-fairly light
Rating of perceived dyspnea	2.8±1.6	2-3	Light

**Note:** The data are presented by mean  $\pm$  SD (n=30).

**Abbreviation:** KKQ, Khon Kaen Qigong group; %HRmax, percentage of maximal heart rate; %VO<sub>2,peak</sub>, percentage of peak oxygen consumption rate.

#### Discussion

To the best of our knowledge, this is the first study to provide evidence that a single bout of KKQ is a very light-intensity exercise, as indicated by very low responses of the cardiorespiratory system in sedentary older participants. Furthermore, KKQ reduced ventilatory efficiency, whereas the reading was confirmed as resting status.

Unexpectedly, the cardiorespiratory responses determined that KKQ was a very light-intensity exercise. Only two subjective indicators i.e. RPE and RPD indicated it as very light- to light-intensity exercise. Together with the other indicator i.e. %HRmax, %VO<sub>2.peak</sub> which is a gold standard indicator of exercise intensity<sup>(19)</sup> classified it as a very light-intensity exercise. The increase in HR compared to the reading group is consistent with a previous study in our laboratory<sup>(6)</sup> (a pilot study). We found that KKQ increased HR along with a trend towards an increased low frequency/high frequency ratio of heart rate variability. This reflects the sympathetic dominance induced by KKQ. Sympathetic activity stimulates cardiac frequency, increasing HR<sup>(20)</sup>. However, it is surprising that KKQ did not increase BP compared with the reading group. The unaltered change in SBP caused by the KKQ was consistent with the response to cycling during low-intensity exercise in a study by Boonthongkaew et al<sup>(14)</sup>. The increased HR but not SBP may be due to the sinoatrial node, which generates HR and is more sensitive to exercise-induced sympathetic activity or hormonal stimulation than the left ventricular muscle, which increases SBP<sup>(20)</sup>. In addition, the unchanged DBP may be explained by the fact that KKQ may not stimulate sufficient vasodilators, such as nitric oxide.

All movements of the KKQ included bending forward, backward, sideward, twisting, and walking. This provides good stretching of the chest, waist, arms, and legs. Furthermore, the KKQ included breathing exercises with pursed lips. Together with stretching in the chest area, KKQ enhances thoracic cage flexibility, resulting in increased inspiratory volumes. Therefore, it increases the concentration of inspired oxygen. The increased KKQ-induced VO<sub>2</sub> reflects increased aerobic metabolism possibly led to enhanced aerobic performance<sup>(21)</sup>. Furthermore, we found that V<sub>F</sub>/VCO<sub>2</sub> decreased from baseline throughout the single bout of KKQ, whereas  $V_E/VO_2$  decreased at 10 min of KKQ compared with the CG. Together with the decreased  $V_E/VCO_2$  and  $V_E/VO_2$  during the KKQ session, the increases in RPE and RPD confirm improved ventilatory efficiency secondary to KKQ. Importantly, it has been shown that exercise-induced decreased ventilatory efficiency are associated with decreased cardiovascular risk and mortality<sup>(22,23)</sup>. Therefore, we expect that KKQ training may benefit cardiovascular risk and mortality.

Considering the importance of quality of the measurement process, we controlled them throughout. Firstly, this study design is RCT which is a good research design, and we blinded all participants and researchers except those who collected the data during KKQ/Reading. Secondly, the quality of all equipment was controlled by calibration before data collection or having quality assessment during the analysis. Thirdly, we matched all baseline characteristics of participants confirmed by results of no difference between groups (Table 1). Furthermore, the ratio of participants' underlying diseases in CG and KKG was similar (five and three participants with diabetes mellitus type 2; 18 and 17 participants with hypertension, and 27 participants in both groups with dyslipidemia). Therefore, these data were sufficient to confirm the results of this study.

First of our limitations, we did not measure autonomic activity, stress hormone concentration, or vasodilator use. This conceals the mechanism of cardiorespiratory responses to both conditions in older sedentary adults. Furthermore, we did not record the HR during KKQ/reading and recovery every 5 min. We measured the HR before and immediately after activities and recovery. Therefore, we could not show a 5-min change in HR during either activity. Therefore, the HR data were inconclusive. However, other indicators, i.e., %VO<sub>2.peak</sub>, RPE, and RPD, showed the very light exercise intensity nature of KKQ. In addition, although we did not have a direct measurement of VO<sub>2.peak</sub>, i.e., cardiopulmonary exercise test (CPET), we used other indirect indicators, i.e., calculated VO<sub>2.peak</sub> from 6 MWT<sup>(24)</sup>, %HRmax, RPE, and RPD which are standard tools. Measuring  $VO_{2,peak}$  from a 6 MWT, a moderate-intensity exercise, is safer for older individuals compared to the direct measurement, i.e., CPET, where participants need to exercise until 85%HRmax or exhaustion<sup>(25)</sup>. Lastly, most participants were female (28 females in the KKG and CG, respectively). A review article demonstrated that sex influences physiology, pathology, and treatment outcomes<sup>(26)</sup>. Thus, our results are unlikely to apply to the male population.

Based on previous studies showing beneficial effects of very low-intensity exercise on cardiorespiratory function<sup>(27-29)</sup>, further studies applying KKQ training to investigate cardiorespiratory responses such as heart rate variability, respiratory muscle strength, and dynamic pulmonary functions and cardiovascular risk factors in older adults worth performing. In addition, the training research in other populations, such as male participants, elderly adults, and patients with cardiovascular and pulmonary diseases should be encouraged.

#### Conclusion

This study demonstrated that a single bout of KKQ is a very light-intensity exercise in sedentary older adults, as indicated by the cardiorespiratory responses to a very low level of effort. Furthermore, it decreases ventilatory efficiency, associated with cardiorespiratory risk factors. Further studies on KKQ training may confirm its impact on cardiovascular disease interventions.

#### **Clinical implication**

- Khon Kaen Qigong (KKQ) is a very lightintensity exercise indicated by increased cardiorespiratory responses to very low levels in sedentary older participants.
- KKQ decreased ventilatory efficiency, implying a reduction in cardiorespiratory risk factors.

#### **Conflicts of interest**

The authors declare no conflict of interest.

#### Acknowledgements

This study was supported by Faculty of Medicine, Exercise and Sport Sciences Development and Research Group (ESRG), Khon Kaen University, Thailand. We would like to thank Editage (www. editage.com) for English language editing. We thank all participants for their participation throughout the study. This study was funded by Research and Graduate Studies Affairs; Khon Kaen University, Thailand.


#### References

- 1. World Population Aging 1950-2050. United Nations Population Division.
- Zhou M, Zhao G, Zeng Y, Zhu J, Cheng F, Liang W. Aging and Cardiovascular Disease: Current Status and Challenges. Rev Cardiovasc Med 2022; 23(4): 135.
- 3. Mannino DM, Davis KJ. Lung function decline and outcomes in an elderly population. Thorax 2006; 61(6): 472-7.
- Anderson L, Thompson D, Oldridge N, Zwisler A, Rees K, Martin N, et al. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev 2016; 2016(1): CD001800.
- Sherrington C, Moseley AM, Herbert RD, Elkins, MR, Maher CG. Editorial: Ten years of evidence to guide physiotherapy interventions: Physiotherapy evidence database (PEDro). Br J Sports Med 2010; 44(12): 836-7.

- Liu G, Premsri N, Tong-un T, Sespheng A, Teparak C, Nonsa- ard R, et al. Acute Effect of Novel Mind-Body Exercise on Heart Rate Variability in Older Adults. JEPonline 2022; 16(3): 84.
- Zhang YP, Hu RX, Han M, Lai BY, Liang SB, Chen BJ, et al. Evidence Base of Clinical Studies on Qi Gong: A Bibliometric Analysis. Complement Ther Med 2020; 50: 102392.
- Zhang F, Bai YH, Zhang J. The Influence of "wuqinxi" exercises on the Lumbosacral Multifidus. J Phys Ther Sci 2014; 26(6): 881-4.
- Wei X, Xu A, Yin Y, Zhang R. The potential effect of Wuqinxi exercise for primary osteoporosis: A systematic review and meta-analysis. Maturitas 2015; 82(4): 346-54.
- Tao J, Chen X, Egorova N, Liu J, Xue X, Wang Q, al. Tai Chi Chuan and Baduanjin practice modulates functional connectivity of the cognitive control network in older adults. Sci Rep 2017; 7: 41581.
- Chen X, Marrone G, Olson TP, Lundborg CS, Zhu H, Wen Z, et al. Intensity level and cardiorespiratory responses to Baduanjin exercise in patients with chronic heart failure. ESC Heart Fail 2020; 7(6): 3782-91.
- 12. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2001; 38(7): 2101-13.
- ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: Guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166: 111-7.
- 14. Boonthongkaew C, Tong-un T, Kanpetta Y, Chaungchot N, Leelayuwat C, Leelayuwat N. Vitamin C supplementation improves blood pressure and oxidative stress after acute exercise in patients with poorly controlled type 2 diabetes mellitus: A randomized, placebo-controlled, cross-over study. Chin J Physiol 2021; 64(1): 16-23.

- 15. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982; 14: 377-81.
- 16. Kendrick KR, Baxi SC, Smith RM. Usefulness of the modified 0-10 Borg scale in assessing the degree of dyspnea in patients with COPD and asthma. J Emerg Nurs 2000; 26(3): 216-22.
- Phillips DB, Collins SÉ, Stickland MK. Measurement and Interpretation of Exercise Ventilatory Efficiency. Front Physiol 2020; 11: 659.
- 18. Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee IM, et al. American College of Sports Medicine. American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. Med Sci Sports Exerc 2011; 43(7): 1334-59.
- Suwabe K, Byun K, Hyodo K, Reagh ZM, Roberts JM, Matsushita A, et al. Reply to Gronwald et al.: Exercise intensity does indeed matter; maximal oxygen uptake is the gold-standard indicator. Proc Natl Acad Sci USA 2018; 115(51): E11892-3.
- 20. Guyton AC, Hall JE. Textbook of medical physiology. Philadelphia: Saunders; 2012.
- 21. Conraads VM, Pattyn N, De Maeyer C, Beckers PJ, Coeckelberghs E, Cornelissen VA, et al. Aerobic interval training and continuous training equally improve aerobic exercise capacity in patients with coronary artery disease: The SAINTEX-CAD study. Int J Cardiol 2015; 179: 203-10.
- 22. Lan C, Chou SW, Chen SY, Lai JS, Wong MK. The aerobic capacity and ventilatory efficiency during exercise in Qigong and Tai Chi Chuan practitioners. Am J Chinese Med 2004; 32(1): 141-50.

- Yılmaz BC, Güçlü MB, Keleş MN, Taçoy GA, Çengel A. Effects of upper extremity aerobic exercise training on oxygen consumption, exercise capacity, dyspnea and quality of life in patients with pulmonary arterial hypertension. Heart Lung 2020; 49(5): 564-71.
- 24. Šagát P, Kalčcik Z, Bartik P, Šiška L', Štefan L. A Simple Equation to Estimate Maximal Oxygen Uptake in Older Adults Using the 6 min Walk Test, Sex, Age and Body Mass Index. J Clin Med 2023; 12(13): 4476.
- 25. Albouaini K, Egred M, Alahmar A, Wright DJ. Cardiopulmonary exercise testing and its application. Postgrad Med J 2007; 83(985): 675-82.
- 26. Miller VM. Why are sex and gender important to basic physiology and translational and individualized medicine? Am J Physiol Heart Circ Physiol 2014; 306(6): H781-826.
- Cetthakrikul S, Nawarat J, Nissapatorn V, Pereira MD, Rungruangbaiyok C. The intensity of arm swing exercise with music-movement synchrony in untrained young adults. Physiother Quart 2023; 31(4): 61-9.
- Ladawan S, Burtscher M, Wannanon P, Leelayuwat N. The Intensity of Qigong Exercise. JEPonline 2018; 21(2): 100-15.
- 29. Sespheng A, Songsaengrit B, Aneknan P, Tong-un T, Tunkamnerdthai O, Leelayuwat N. Effects of Modified Arm Swing Exercise on Pulmonary and Autonomic Nervous Functions in Patients with Metabolic Syndrome. JEPonline 2018; 21(6): 26-40.



#### Supplementary

Figure S1 Postures of Khon Kaen Qigong (Figure reproduced with permission from Liu et al, 2022).



**CONSORT 2010 Flow Diagram** 




Figure S2 Consort flow diagram of this study.

Abbreviation: KKG, Khon Kaen Qigong group; CG, control group.




Figure S3 %VO<sub>2peak</sub> during Khon Kaen Qigong.

Abbreviation:  $%VO_{2peak}$ , percentage of peak oxygen consumption rate.

Arch AHS

Archives of Allied Health Sciences 2024; 36(1): 25-39.

### An Excel Visual Basic for Application worksheet for automatic selection of a sigma statistical quality control procedure, facilitating quality management for laboratories

#### Pranadta Wontong\*

Department of Chemistry, Laboratory, Prasat Hospital, Surin, Thailand.

KEYWORDS Sigma metric; Statistical quality control; QC plan tool; Quality management.

#### ABSTRACT

Defining the proper statistical quality control (SQC) procedure and designing the quality control plan provide the analytical quality management (QM) that is essential in laboratory practice, ensuring that reported test results achieve the quality required for medical decisions. The Westgard sigma rules with run size, one of the popular quality control planning tools, is an effective tool for evaluating measurement performance and simplifying an appropriate selection of SQC. To achieve QM, the author established an Excel Visual Basic for Application (VBA) worksheet for automatic sigma scale calculation and automatic selection of SQC procedures. This file applied the Westgard sigma rules with run size concept, developed for a convenient multistage SQC design. In addition, there are more functions for monitoring QC results, documenting, and compiling the corrections utilized to improve QC design. Of 23 assays from our laboratory, only one-fifth of the tests (22%) achieved an optimal level of performance ( $\geq$  6 sigma). Analytes with the highest sigma performance were triglyceride, high-density lipoprotein (HDL), low-density lipoprotein (LDL), magnesium (Mg) and creatine phosphokinase (CK). In contrast, one-third of the tests (35%) had a sigma scale of less than 4, requiring them to be solved, improved and have rigorous QC monitoring by primary following in the Data Analysis sheet. Thus, this Excel VBA worksheet is an alternative tool for simplifying analytical QM that is effectively controlled and convenient, with multistage SQC designs.

\*Corresponding author: Pranadta Wontong, MT, BSc. Department of Chemistry Laboratory, Prasat Hospital, Surin, Thailand. Email address: pranadta.lab@gmail.com

Received: 6 July 2023/ Revised: 27 October 2023/ Accepted: 5 January 2024

#### Introduction

Statistical quality control (SQC) is an essential laboratory practice to ensure reported test results achieve the guality required for medical decisions. Laboratories need the optimal SQC to provide a procedure to detect performance changes, potentially causing medically important errors. SQC practice is the evaluation of analytical quality control as a part of quality management. Sigmametric is the popular quality control planning tool employed for process improvement. In 1986 Bill Smith was the person who applied the six sigma statistic for quality improvement methodology to the Motorola company<sup>(1)</sup>. Westgard JO is developing QC design and planning tools to support laboratory efforts to select SQC procedures, such as the "Westgard sigma rule for QC design and Run size"<sup>(2)</sup>.

Rosenbaum MW et al carried out a survey about quality control practices for chemistry and immunochemistry in a cohort of 21 large academic medical centers in America in 2018, which revealed that most hospitals (76%) used a rule such as 2 SD to monitor QC results, which is not recommended because of causing a high probability a false rejection, and only 10% used multi-Westgard rules based on the performance of an assay  $^{\!\!\!(3)}\!\!$  . Westgard JO discusses that this survey is a disappointing finding, but not entirely unexpected because there may be a variety of explanations, such as the guideline is too expensive, does not provide a practical methodology to implement the recommended principles and approach, is too difficult to understand because of the statistical and theoretical nature of the subject, or laboratories are not interested in a quantitative SQC planning methodology. They are still making available new graphical tools and worksheets that are simple recommendations for running QC<sup>(4)</sup>.

In 2021 Westgard et al announced the report of the Global QC Practice survey, which was used in more than 600 laboratories from more than 100 countries. Most laboratories still used 2 SD as the primary rule for QC techniques and Westgard rules for observing QC that utilized those limits for all assays. For determining the control limit, the majority of laboratories calculated the actual mean and the actual SD to create Levey-Jennings control charts, which is the proper procedure. However, the others perform using the manufacturer's range, which is quite wide for detecting the error. In determining control material, most laboratories use the controls provided by manufacturers. Although the recommendation from CLSI is a third-party process, it is the second most popular control type. Concerning the frequency of running QC, most laboratories follow the standard from CLSI, which is once-a-day QC, followed by running twice a day, and three times a day. Even though more frequent running QC has earlier error detection, it comes with a higher budget in the process<sup>(5)</sup>.

From a survey in 2018 to the Global QC practices survey in 2021, Westgard opined that "Laboratories know they should do the right thing, whereas they are unable to utilize them routinely. We think one the reason for this gap between theory and practice is the complexity of the theory and the lack of practical tools to help laboratories apply the evidence-based approach". The author took up this challenge to create practical tools, such as an Excel VBA worksheet, to simplify the theory for alternative implementation customizing the QC for each assay's sigma performance, thus improving QC planning as a part of the quality management system (QMS).

#### Materials and methods

#### Materials

In this study, control results were analyzed with Mindray ClinChem Multi Control level 1 and level 2 by Mindray BS-800 analyzer that was used to perform 23 routine biological assays: sodium (Na), potassium (K), chloride (Cl), glucose (Glu), urease (Urea), creatinine (Crea), uric acid (UA), total cholesterol (TC), triglyceride (TG), highdensity lipoprotein (HDL), low-density lipoprotein (LDL), total protein (TP), albumin (ALB), total bilirubin (T-Bili), aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), calcium (Ca), magnesium (Mg), phosphorus (P), amylase (AMY), creatine kinase (CK), and lactate dehydrogenase (LDH). The protocol was approved by the Ethics Committee of Prasat Hospital (PSH REC No. 004/2023).

#### Study design and participants

Brew6sigma, an implementation of an Excel VBA worksheet that is used in this study, used Microsoft Excel 2016, integrated with the Westgard sigma rule for QC design and Run size, which provides simplicity of sigma metric calculation and the design of statistic quality control (SQC) tools to support analytical quality management (Figure 1). The SQC procedure selects the optimized control rules and the number of control measurements to detect medically important errors. Designing a QC plan to integrate SQC is needed to monitor failure modes in analytical methods or instrument systems. Brew6sigma is the alternative of the practical tool with the PDCA cycle concept, to help laboratories apply the complicated six sigma quality management system that adheres to the Thai medical technology standard 2022, corresponding to ISO 15189 standards. The components of a Brew6sigma VBA worksheet include the Index sheet, typically serving as a table of contents for the program, Data Analysis sheet, Summarize sheet, Control level 1 sheet, Control level 2 sheet, Bias sheet, Corrective Action sheet, and Test sheet.

The Data Analysis sheet asks the user to enter the data of TEa, defined from three source recommendations for setting a quality goal or quality requirement, CLIA CAP and Rico, and fill up in-house data that consists of mean, SD and bias in each test for sigma metric calculation. From in-house data, mean and SD are determined on a replication experiment. The CV refers to the "coefficient of variation", which describes the standard deviation as a percentage of the mean, as shown in the following equation:

#### CV% = (SD/mean) x 100

The CLSI guideline defines the criteria for acceptable CV from the repeatability that the experimental product has at least 20 replicates collected over 20 days (between-runs) and should be less than or equal to thirty-three percent of TEa<sup>(6)</sup>.




Figure 1 Flow diagram illustration of how the automatic SQC selection process works. Note: 'The part for the user to enter data and documentation of correction, "The part of the Excel VBA worksheet that automatically calculates the sigma metric and automatically selects the proper SQC procedure.

In this program, the sigma metric was calculated with the following equation:


SM = (TEa% - Bias%) / (CV%)

Where TEa represents the allowable total error. Bias and CV represent systemic and random errors, respectively. Thus, the Excel VBA will select an appropriate SQC from the calculated sigma metric or sigma scale, referenced from the Westgard sigma rule for QC design and run size performance of method decision level, Westgard rules, run size (number of patients), number of control measurements and frequency of runs (Table 1). In addition, if the sigma scale is less than six, which may result in more defects, the program will calculate the quality goal index (QGI) by evaluating the root of causing errors, by the following expression:

QGI = Bias / 1.5 CV

The QGI ratio represents bias or precision that achieves its quality goals. The quality goals chosen for use are 1.5\*TEa/6 for bias and TEa/6 for precision. A high QGI ratio means that bias exceeds its accuracy goal, while imprecision meets its precision goal. On the contrary, a low QGI ratio means that bias meets its accuracy goal while imprecision exceeds its precision goal. The criteria are for interpreting QGI when the sigma metric is less than six, as the calculated QGI is less than 0.8 and more than 1.2, presenting the cause of the problem by imprecision and inaccuracy, respectively, while QGI between 0.8-1.2 presents the cause of the problem by both imprecision and inaccuracy<sup>(7)</sup>.

The Summarize sheet performs the individualized sigma metric, method decision level, and optimal SQC procedure (consisting of the control rules, number of controls, and run size of patient needed) in each test along with an automatic pie chart of sigma proportion. The user will provide the individual normalized method decision chart by filling in the test name in the field (Figure 2). In the Control level 1 and Control level 2 sheets, the user must input control data to prepare to create Levey-Jennings control charts. In addition, this Excel VBA calculates the cumulative mean, SD and CV. The cumulative CV is a long-term estimate of the central tendency observed for a control material, based on a large number of control measurements collected over a long period ( $\geq$  6 months). Comparing the monthly CV to the cumulative CV, if the monthly CV is more than twice the cumulative CV, then it should be investigated and documented. Any significant change may indicate a change in instrument calibration or a fault in its function.



test_name	%CV of TEa	%Bias of TEa
Na	26.22	46.40
К	26.32	36.00
Cl	26.24	47.40
Glucose	19.74	7.25
Urea	27.16	15.67
Creatinine	19.39	20.50
Uric Acid	15.64	30.80
Cholesterol	25.27	41.00
Triglyceride	12.70	16.40
HDL	16.28	2.05
LDL	12.50	11.30
Total Protein	32.16	50.50
Albumin	20.24	15.00
Total Bilirubin	17.47	12.30
AST	19.75	4.80
ALT	17.24	12.80
ALP	21.04	23.45
Са	16.28	13.20
Р	22.30	31.60
Mg	13.92	2.53
Amylase	16.29	16.25
LDH	20.43	12.73
СК	13.33	17.70

**Figure 2** The automatically plotted operating point when entering the named test in the table. **Note:** "Normalized" Method decision chart observed inaccuracy is calculated as 100\*bias/TEa and imprecision is calculated as 100\*CV/TEa, where original parameters are all in units of %.

The Bias sheet collects monthly bias data and is convenient for summary and usage. Bias, inaccuracy, trueness or systemic error is determined during method validation studies from method experiment comparison. The laboratories should perform experiments to verify a manufacturer's claim after installation. After initial validation, laboratories require monitoring bias using EQA/ PT samples with target values or assigned values, established by reference methods or the mean of the survey group (peer group). The user must fill up this sheet with their results and the assigned result, which is measured by the same method and instrument for bias calculation. In the calculation of the sigma metric, this worksheet calculates bias with the following equation:

%Bias = (Your result - Assigned result)/ (Assigned result x 100)

To establish the corrective action, the Corrective Action sheet documents and collects corrections that solve the error or are out of control from all the operating tests.

Test sheets specify the standard quality control chart or the Levey-Jennings chart, which is computed from the mean and SD determined in the laboratory by a method operating under stable conditions. The Levey-Jennings chart provides monitored and interpreted control results under the right SQC. This sheet presents a control chart as a z-score chart in which individual control results are calculated for the z-score and plotted on the y-axis versus time on the x-axis. The z-score shows the standard deviation of a control result from the expected mean value, which is determined by the following expression:

z-score = (value - mean) / SD

A z-score chart is typically created as the mean (z-score is 0) plus or minus a certain multiple of the SD, commonly  $\pm$  3SD,  $\pm$  2SD or and  $\pm$  1SD. It is expected that 99.7% (i.e. almost all) control results fall within the mean  $\pm$  3 SD limits, whereas about 95% are expected within the mean  $\pm$  2 SD limits, and 67% within the mean  $\pm$  1 SD<sup>(8)</sup>. As a result, this worksheet interprets control results

using optimal SQC procedure from the calculated data in the Data Analysis sheets (as shown beside the z-score chart). In addition, it can interpret control results as violations based on the fully cataloged number of ways that can break the "Westgard rules"<sup>(9)</sup> and record corrections to establish corrective action. Doing the proper SQC observation and monitoring control results are components of the quality control plan, which is helpful for quality management.

#### Results

The performances, sigma values and right SQC of the 23 assays in the Mindray BS800 analyzer are used in the Excel VBA worksheet for automatic calculation of the sigma scale and automatic selection of the SQC procedure presented by in-house data of the laboratory at Prasat Hospital, as shown in the Data Analysis sheet (Table 1).

The summarized sigma metric in each test is divided by class, performed in table 2, and shown as a pie chart from the proportion of sigma in the supplement part. Only one-fifth of the test (22%) achieved an optimal level of performance ( $\geq$  6 sigma). Analytes with the highest sigma performance were triglyceride, HDL, LDL, Mg and CK. The assays with sigma  $\geq$  5 (17.39%) are excellent, and sigma  $\geq$  4 (26.09%) are good. In contrast, one-third of the tests (35%) with a sigma scale of less than 4 need to be fixed, improved and have rigorous QC monitoring by primarily following the Data Analysis sheet (Table 1).

Data Analysis sheet
ij.
display i
SQC
al
ited sigma metric and optim
l sigma n
calculatec
individual
data, i
In-House
Ţ
Table '

								)			•		,	-	•						
Test	TEa	83%TEa	t_ns∍m	r_as	×۱۷⊃	2_nsəm	z-as	CV2*	Precision check	ssid	*tsmgi2	*Semgi2	*smgi2 xi2	**bəsilised Mormalized	**R, R, R	**2əluЯ	Run Size ** (Patient samples)	ɗel↓***	<b>ઉ</b> €IΣ***		Problem
Na	2	1.65	114.4	1.5	1.31	137.5	1.8	1.31		2.32 2	2.04	2.05	2.04	Poor	N;6,R;1	13s; 22s;	45	1.18	1.18	Imprecision	ision &
															(N;2,R;3)	R4s; 41s; 8x				Inaccuracy	acy
¥	9	1.98	3.80	0.06	1.58	6.978	0.11	1.58	~	2.16 2	2.43	2.44	2.43	Poor	N;6,R;1	13s; 22s;	45	0.91	0.91	Imprecision &	ision &
															(N;2,R;3)	R4s; 41s; 8x				Inaccuracy	acy
כו	5	1.65	92.8	1.14	1.23	109	1.43	1.31	~	2.37 2	2.14	2.00	2.00	Poor	N;6,R;1	13s; 22s;	45	1.29	1.20	Inaccuracy	acy
															(N;2,R;3)	R4s; 41s; 8x					
Glucose	8	2.64	101	1.44	1.43	245	3.87	1.58	~	0.58	5.20	4.70	4.70	Good	N;4,R;1	13s; 22s;	200	0.27	0.24	Imprecision	ision
															(N;2,R;2)	R4s; 41s					
Urea	6	2.97	19.8	0.46	2.32	58.5	1.43	2.44	~	1.41	3.27	3.11	3.11	Marginal	N;6,R;1	13s; 22s;	45	0.40	0.38	Imprecision	ision
															(N;2,R;3)	R4s; 41s; 8x					
Creatinine	10	3.3	0.877 0.017	0.017	1.94	3.52 (	0.065	1.85	~	2.05 4	4.10	4.31	4.10	Good	N;4,R;1	13s; 22s;	200	0.70	0.74	Imprecision	ision
															(N;2,R;2)	R4s; 41s					
Uric Acid	10	3.3	5.14	0.07	1.36	10.87	0.17	1.56	~	3.08	5.08	4.42	4.42	Good	N;4,R;1	13s; 22s;	200	1.51	1.31	Inaccuracy	acy
															(N;2,R;2)	R4s; 41s					
Cholesterol	10	3.3	91	2.3	2.53	182	3.17	1.74	~	4.10 2	2.33	3.39	2.33	Poor	N;6,R;1	13s; 22s;	45	1.08	1.57	Imprecision &	ision &
															(N;2,R;3)	R4s; 41s; 8x				Inaccuracy	acy
Triglyceride	15	4.95	113	1.6	1.42	210	4	1.90	~	2.46 8	8.86	6.58	6.58	World Class	N;2,R;1	13s	1000				
HDL	20	6.6	27.65	0.9	3.26	60	1.5	2.50	<	0.41 6	6.02	7.84	6.02	World Class	N;2,R;1	13s	1000				
LDL	20	6.6	58	1.3	2.24	120	č	2.50	~	2.26 7	7.91	7.10	7.10	World Class	N;2,R;1	13s	1000				
Total Protein	8	2.64	4.68	0.12	2.56	8.55	0.22	2.57	~	4.04	1.54	1.54	1.54 (	Unacceptable	N;6,R;1	13s; 22s;	45	1.05	1.05	Imprecision &	ision &
															(N;2,R;3)	R4s; 41s; 8x				Inaccuracy	acy
Albumin	8	2.64	3.03	0.046 1.52	1.52	5.25 (	0.085	1.62	~	1.20 4	4.48	4.20	4.20	Good	N;4,R;1	13s; 22s;	200	0.53	0.49	Imprecision	ision
															(N;2,R;2)	R4s; 41s					
Total Bilirubin	20	6.6	1.15	0.04	3.48	4.58	0.16	3.49	~	2.46	5.04	5.02	5.02	Excellent	N;2,R;1	13s; 22s; R4s	450	0.47	0.47	Imprecision	ision
AST	15	4.95	51	1.5	2.94	162	4.8	2.96	~	0.72	4.86	4.82	4.82	Good	N;4,R;1	13s; 22s;	200	0.16	0.16	Imprecision	ision
															(N;2,R;2)	R4s; 41s					
ALT	15	4.95	58	1.5	2.59	144	3.7	2.57	<	1.92	5.06	5.09	5.06	Excellent	N;2,R;1	13s; 22s; R4s	450	0.49	0.50	Imprecision	ision
ALP	20	6.6	84.5	3.5	4.14	202	8.5	4.21	~	4.69 3	3.70	3.64	3.64	Marginal	N;6,R;1	13s; 22s;	45	0.75	0.74	Imprecision	ision
															(N;2,R;3)	R4s; 41s; 8x					

Test	5 TEa	33%TEa	t_ns∍m	r_as	*rvɔ	∑_ns∍m	z <sup>-</sup> as	CV2*	Precision chec	seid	*1.smgi2	*Semgi2	*smgi2 xi2	Normalized** Method Decision	и, R**	**səluЯ	** əzi2 nnЯ (Patient sample	QGI1***	ɗ€I5∗∗∗	Problem
Ca	10	3.3	8.6	0.14	1.63	12.9	0.17	1.32	<b> </b> \	1.32	5.33	6.59	5.33	Excellent	N;2,R;1	13s; 22s; R4s	450	0.54	0.67	Imprecision
Ь	10	3.3	4.30	0.09 2.09		8.07	0.18	2.23	~	3.16	3.27	3.07	3.07	Marginal	N;6,R;1	13s; 22s;	45	1.01	0.94	Imprecision
															(N;2,R;3)	R4s; 41s; 8x				& Inaccuracy
Mg	15	4.95	2.03	0.04 1.97		3.35	0.07	2.09	~	0.38	7.42	7.00	7.00	World Class	N;2,R;1	13s	1000			
Amylase	20	6.6	85.7	2.5	2.92	221	7.2	3.26	~	3.25	5.74	5.14	5.14	Excellent	N;2,R;1	13s; 22s; R4s	450	0.74	0.67	Imprecision
LDH	15	4.95	149	4	2.68	261	8	3.07	~	1.91	4.88	4.27	4.27	Good	N;4,R;1	13s; 22s;	200	0.47	0.42	Imprecision
															(N;2,R;2)	R4s; 41s				
CK	20	20 6.6 150 4 2.67	150	4	2.67	258	5.7	2.21 / 3.54	~	3.54	6.17	7.45	6.17	World Class	N;2,R;1	13s	1000			

number of controls (N), number of runs (R), rules and the number of patient samples (Run size), "" If sigma scale is less than 6, the calcu-

lated value from CV and bias is presented by the QGI ratio defining the root of the error.

Table 1 In-House data, individual calculated sigma metric and optimal SQC display in Data Analysis sheet (Cont.)

32

Sigma	Test (n)	%	Test
6	5	21.74	Triglyceride, HDL, LDL, Mg, CK
5	4	17.39	Total-bilirubin, ALT, Ca, Amylase
4	6	26.09	Glucose, Creatinine, Uric, Albumin, AST, LDH
< 4	8	34.78	Sodium, Potassium, Chloride, Urea nitrogen, Cholesterol, Total protein, ALP, P

Table 2 Summary number of sigma metric classifications by the decision method

A summary bias table in the Bias sheet supports collecting and monitoring accuracy or frequency of EQA/PT in each test. There are user-editable bias value choices for sigma scale calculation. The Corrective Action sheet performs all of the corrections from all of the tests that utilize implementation and records the violation of QC results in each test sheet by the user for improving QC. Summarized corrections are shown as a table for creating owner laboratory guidelines to solve the problem. Each test sheet presents a z-score chart and summary data, including mean, SD, CV, bias, sigma metric, method decision, rules, N, R and Run size from table 1, to interpret the QC result for monitoring precision or detecting random error. The QC results as 2 levels are documented in the Control level 1 sheet and Control level 2 sheet for creating a z-score chart and calculating cumulative CV that monitors the shift or drift of control results (Figure 3).




Figure 3 The display of the triglyceride sheet (test sheet).

# Discussion

There are several main reasons to explain the differences in sigma metric found in this research, such as 1) the difference of source selected for the TEa target, 2) the difference between the algorithms used to evaluate CV and bias, and 3) the different selection sigma metric between 2 or more control levels.

For the Sigma metric, determining the TEa goals should be made carefully, as neither standardization nor harmonization of the existing resources for TEa goals exists<sup>(10)</sup>: Clinical Laboratory Improvement Amendments (CLIA), College of America Pathologists Participant (CAP), Royal College of Pathologists of Australasia and the Australasian Clinical Biochemist Association Quality Assurance Program (RCPA), Ricos' biological variability. Each TEa has a direct impact on the sigma metric.

The coefficient of variation (CV%) describes the variation of a test that is expressed as a percentage of the mean and calculated as CV% =  $(SD/mean) \times 100$ . When the SD increases in proportion to concentration, the CV will increase. Likewise, the level of concentration relates to CV as in lower concentrations the CV may be higher, and at higher concentrations, the CV may be lower<sup>(11)</sup>. Thus, the right target values or mean concentrations should be close to medical decision levels (MDLs), and the right sigma metric should be calculated from the CV at the concentration that hits the MDLs<sup>(12)</sup>. However, multianalyte controls with 20 or more analytes will be unlikely to hit the MDLs for all of them. In addition, the real concentration of control will be less or over the MDLs. The guideline for choosing the CV to calculate the sigma metric is if all of the controls in each test have a concentration near MDLs, the mean of all CV is used, and if any value is nearest to MDLs, then its CV concentration is used.

Considering the selection sigma metric between 2 or more control levels, for example, Peng S et al calculated the sigma metric and selected the optimal SQC for each control level, then monitored the quality control following each optimal SQC. It is difficult and complicated for the operator because of the differences in sigma value between the levels of control<sup>(13)</sup>. From Kumar and Mohan, the CV of individual control level used in the sigma metric was from the average CV value in 12 months. They calculated the sigma metric of each control level with the different sigma metrics. The introduction should be evaluated with discretion, which strictly complies with Westgard multi-rules to abolish discrepancy<sup>(14)</sup>. In conclusion, this study calculated the sigma metric in each test from all concentration levels, then chose the least sigma metric for the strongest criteria to monitor QC.

Lastly, The traditional error model as the Plan-Do-Check-Act (PDCA) cycle described by Deming<sup>(15)</sup> provides the basic process for developing, implementing and operating a quality management system (QMS). The Excel VBA worksheet can facilitate the PDCA cycle concept and sigma metric tools for analytical quality management as shown in figure 1.

Plan: (1a) Define quality goals as an allowable total error (TEa). TEa guides the selection of analytic measurement procedures, or examination procedures in ISO terminology.

Do: (1b) Validate safety characteristics (precision and bias) using experimental studies and statistical data analysis. Acceptable performance can be evaluated by determining quality on a Sigma scale using the method decision chart. (2b) Assuming the sigma metric indicates acceptable performance (that is greater than 3, preferably at least 4 and, better yet, 5 or 6) proceed to implement the analytical method.

Check: (1c) The SQC procedure optimizes the control rules, number of controls, number of runs, and number of patient samples (Run size) to detect medically important errors. Design a QC plan to integrate SQC with other control mechanisms that are needed to monitor specific failure modes that may occur with a particular analytic method or instrument system. Act: (1d) Monitor the quality of the testing process over time to characterize performance, identify failures, and improve the QC plan<sup>(16)</sup>.

## Conclusion

The Excel VBA worksheet, which employs Westgard sigma rules with run size, is an alternative tool simplifying analytical QM, including specifying quality goals, judging the acceptability of performance of examination procedures, designing statistical quality control (SQC) procedures to detect significant medical errors that are effectively controlled and convenient with multistage SQC designs. Moreover, this file has a function for monitoring QC results, evaluating quality from external quality assessment and proficiency testing surveys, and establishing corrective action for improving the QC plan.

## Take home messages

This Excel VBA worksheet is suitable for any hospital starting to apply the sigma SQC designs for analytical QM.

## **Conflicts of interest**

The author declares no conflict of interest.

#### Acknowledgments

This work received no specific grant from any funding support. Special thanks to Phongsathorn Wichian, PhD, for his support in my research. I would like to convey my profound gratitude to Khon Kaen University, Faculty of Associated Medical Science, for giving the learning that impacted and inspired me. Lastly, I would like to express my special thanks to my family, my institute, and all the people who have supported me in completing the research work directly or indirectly.

#### References

- 1. Angmo D, Kant S. Six sigma implementation in healthcare industry: Past, present and future. Int J Eng Res Technol 2015; 4: 1078-82.
- Westgard JO, Bayat H, Westgard SA. Planning risk-based SQC schedules for bracketed operation of continuous production analyzers. Clin Chem 2018; 64(2): 289-96.
- Rosenbaum MW, Flood JG, Melanson SEF, Baumann NA, Marzinke MA, Rai AJ, et al. Quality control practices for chemistry and immunochemistry in a cohort of 21 large academic medical centers. Am J Clin Pathology 2018; 150(2): 96-104.
- Westgard JO. A stark reminder about the truth standard for laboratory testing [online] 2018 [cited 2022 April 1]. Available from https://westgard.com/essays/basic-qcpractices/823-truth-standard-qc.html
- Westgard S. The 2021 Global QC Survey Results Are "In" - and "Out" [online] 2021 [cited 2022 April 1]. Available from https:// westgard.com/qc-applications/basic-qcpractices/ 964-2021-global-qc-survey-results. html
- Westgard JO, Carey RN, Wold S. Criteria for judging precision and accuracy in method development and evaluation. Clin Chem 1974; 20(7): 825-33.
- Parry D. Quality Goal Index [online] 2006 [cited 2023 May 1]. Available from: https:// westgard.com/essays/guest-essay/ 179-guest34.html
- Westgard JO. Basic qc practices [online] 2006 [cited 2023 May 1]. Available from: https:// westgard.com/lessons/basic-qc-practices-l /27-lesson14.html
- Westgard S. 50 ways (+) to Break your Westgard Rules [online] 2019 [cited 2022 April 1]. Available from https://westgard.com/ lessons/westgard-rules/862-50-wayswestgard-rules.html
- Westgard S, Bayat H, Westgard JO. Analytical sigma metrics: A review of six sigma implementation tools for medical laboratories. Biochem Med (Zagreb) 2018; 28(2): 020502.

- 11. Westgard JO. Z-4: mean, standard deviation, and coefficient of variation [online] 1999 [cited 2023 May 1]. Available from: https:// westgard.com/lessons/z-stats-basic-statistics /73-lesson34.html
- Westgard JO, Westgard SA. Six sigma quality management system and design of risk-based statistical quality control. Clin Lab Med 2017; 37(1): 85-96.
- 13. Peng S, Zhang J, Zhou W, Mao W, Han Z. Practical application of Westgard sigma rules with run size in analytical biochemistry processes in clinical settings. J Clin Lab Anal 2021; 35: e23665.
- Kumar BV, Mohan T. Sigma metrics as a tool for evaluating the performance of internal quality control in a clinical chemistry laboratory. Journal of Laboratory Physicians 2018;10(2): 194-99.
- Nillson OJ. The essential deming: leadership principles from the father of quality, W. Edwards Deming. New York: McGraw-Hill; 2013.
- Westgard JO, Westgard SA. Six sigma quality management system and design of risk-based statistical quality control. Clin Lab Med 2017; 37(1): 85-96.

# **Supplementary**

# Program interface

The components of a Brew6sigma VBA worksheet include the Index sheet, typically serving as a table of contents for the program, Data Analysis sheet, Summarize sheet, Control level 1 sheet, Control level 2 sheet, Bias sheet, Corrective Action sheet, and Test sheet. When the user clicks each button, the program will run to that page (sheet).

Input the in-house data for the Data Analysis sheet, click the "Fill up" button, and then pop up the entry data window.

																/				
6	Insti	tute	>													-	1			
Brend	supe	rvisor	>						*****							Fill up				
		ormer	>														1			
	perio	Annei	-																	
Test	IFA	33% IFA	mean_1	SD_1	%CV1	mean_2	50_2	%CV2	Precision check	bas	Sigmat	Sigma2	Six Sigma	Normalized Method Decision	NR	Rules	Run Size (Patient samples)	QG1	QS/2	Problem
4a	5	1.65	114.49	1.50	1.311	137.50	1.80	1.309	Acceptable	2.32	2.04	2.05	2.04	Pteor	N;6,R;1(N;2,R;3)	13s; 22s; R4s; 41s; 8x	45	1.18	1.18	Imprecision & Inaccuracy
2	6	1.98	3.80	0.06	1.579	6.98	0.11	1.576	Acceptable	2.16	2.43	2.44	2.43	Poor	N:6.R1(N;2,R3)	13s; 22s; R4s; 41s; 8x	45	0.91	0.91	Imprecision & Inaccuracy
1.	5	1.65	92.80	1.14	1.228	109.00	1.43	1.312	Acceptable	2.37	2.14	2.00	2.00	Poor	N:6.R1(N:2.R3)	13s; 22s; R4s; 41s; 8x	45	1.29	1.20	haccuracy
02	8	2.64	14.18	0.55	3.906	23.60	1.03	4.380	Unacceptable											
lucose	8	2.64	101.00	1.44	1.426	245.00	3.87	1.580	Acceptable	0.58	5.20	4.70	4,70	Good	N:4,R1(N;2,R2)	13s: 22s; R4s; 41s	200	0.27	0.24	Impredision
irea	9	2.97	19.80	0.46	2.323	58.50	1.43	2.444	Acceptable	1.41	3.27	3.11	3.11	Marginal	N:6.R1(N;2,R3)	13s; 22s; RAs; 41s; 8x	45	0.40	0.38	Imprecision
reatinine	10	3.3	0.88	9.07	1.939	3.52	0.07	1.847	Acceptable	2.05	4.10	4.31	4,10	Gend	N;4,R;1 (N;2,R;2)	13q 22q R4q 41c	200	0.70	0.74	Imprecision
Iric Acid	10	3.3	5.14	9.07	1.362	10.87	0.17	1.564	Acceptable	3.08	5.08	4.42	4,42	Good	N:4,R:1 (N;2,R;2)	13s; 22s; R4s; 41s	200	1.51	1.31	haccuracy
holesterol	10	3.3	91.00	2.30	2.527	182.90	3.17	1.742	Acceptable	4.1	2.33	3.39	2.33	Poor	N(6,R(1 (N(2,R(3)	13s; 22s; R4s; 41s; 8x	45	1.08	1.57	Imprecision & Inaccuracy
riglyceride	15	4.95	113.00	1.60	1.416	210.90	4.00	1.905	Acceptable	2.46	8.86	6.58	6.58	World Class	N;2,R;1	136	1000			
IDL.	20	6.6	27.65	9.9C	3.255	60.00	1.50	2.500	Acceptable	0.41	6.02	7.84	6.02	World Class	N;2,R1	13s	1000			
D.	20	6.6	58.00	1.30	2.241	120.00	3.00	2.500	Acceptable	2.26	7.91	7.10	7.10	World Class	N2R1	135	1000			
otal Protein	8	2.64	4.68	0.12	2.564	8.55	0.22	2.573	Acceptable	4.04	1.54	1.54	1.54	Unarceptable	No.6,R1 (No.7,R3)	136; 226; RAG; 416; 8x	45	1.05	1.05	Imprecision & Inaccusacy
Ibumin	8	2.64	3.03	0.05	1.518	5.25	0.09	1.619	Acceptable	1.2	4.48	4.20	6,20	Good	N:4.R:1 (N;2,R;2)	13s: 22s: Rils; 41s	200	0.53	0.49	Imprecision
otal Bilirubin	20	6.6	1.15	0.04	3.478	4.58	0.16	3.493	Acceptable	2.46	5.04	5.02	5.02	Excelient	N2R1	13x 22x R4s	450	0.47	0.47	Imprecision
Direct ISlirubin	-		1.04	0.05	4.879	2.64	0.12	4.545												
ST	15	4.95	51.00	1.50	2.941	162.00	4.80	2.963	Acceptable	0.72	4.86	4.82	4.82	Good	N:4.R1 (N2.B;2)	13s; 22s; Rils; 41s	200	0.16	0.16	Imprecision
LT	15	4.95	58.00	1.50	2.586	144.00	3.70	2.569	Acceptable	1.92	5.06	5.09	5.06	Excellent	N:2R1	13x 22x 84s	450	0.49	0.50	Imprecision
IP.	20	6.6	84.50	3.50	4,142	202.00	8.50	4.208	Acceptable	4.69	3.70	3.64	3.64	Marginal	N:6JR1 (N2,R3)	136; 226; R45; 415; 8x	45	0.75	0.74	Imprecision
a	10	3.3	8.60	0.14	1.628	12.90	0.17	1.318	Acceptable	1.32	5.33	6.59	5.33	Excellent	N2R1	13s. 22s. Rils	450	0.54	0.67	Imprecision
	10	3.3	4.30	9.09	2.091	8.07	0.18	2.230	Acceptable	3.16	3.27	3.07	3.07	Marginal	N(6,R)1 (N(2,R)3)	13s; 22s; RAs; 41s; 8x	45	1.01	0.94	Imprecision & Inaccuracy
10	15	4.95	2.03	0.04	1,970	3.35	0.07	2.087	Acceptable	0.38	7.42	7.00	7,00	World Class	N2.R1	135	1000			
misse	20	6.6	85.70	2.50	2.917	221.00	7.20	3.258	Acceptable	3.25	5.74	5.14	5.14	Excelient	N281	135, 225, 845	450	0.74	0.67	Imprecision
DH	15	4.95	149.00	4.00	2.685	261.00	8.00	3.065	Acceptable	1.91	4.88	4.27	4.27	Good	N:4.R1 (N2.R2)	13x 22x 84x 41x	200	0.47	0.42	Imprecision
X	20	5.6	150.00	4.00	2.667	258.00	5.70	2.209	Acceptable	3.54	6.17	7.45	6.17	World Class	N2R1	135	1000		0.4	and the second
SP	-		9.45	0.50	5.291	66.00	2.60	3.939												
IbA1c	8	2.64	4.90	0.10	2.041	10.00	0.20	2,000	Acceptable	0.5	3.68	3.75	3.68	Marginal	N(6,R1 (N(2,R)3)	136; 226; R45; 415; 8x	45	C.16	0.17	Imprecision
				0.15		10.00	0.00	2000	raceposee.		0.00		0100			Log Log The Log Co.			0.11	and second of
	-				-	-	-												-	
	-					-										-				
	-			-		-						-								
	-			-		-				-									-	
	<u> </u>			-		-	-													
	<u> </u>			-		-	-													
	-					-	-												-	
				-		-	-			-							_	-	-	
	-			-		-			_	-									-	-

7	
Entry Data	
	CILLIN COL
	Fill Up !
Test name	*::::
	· · · · · · · · · · · · · · · · · · ·
TEa	
Bias	
listing level 1	
mean 1	1
∎ <u></u>	
SD 1	
50_1	
• · · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·
mean 2	
SD 2	
JD_2	.:
••••••••••••••••••••••••••••••••••••••	• • • • • • • • • • • • • • • • • • •
Searc	h Clear
Jearc	Cical
Add Da	ta Delete
	Exit
•	

Figure S1 Data Analysis sheet and entry data window.

Click the "Add Data" button for the calculation sigma metric. Thus, the Excel VBA will select an appropriate SQC from the calculated sigma metric or sigma scale, referenced from the Westgard sigma rule for QC design and run size performance of method decision level, Westgard rules, run size (number of patients), number of control measurements and frequency of run.

The Summarize sheet calculates the individualized sigma metric, method decision level and optimal SQC procedure (consisting of the control rules, number of control results, and run size of patients needed) in each test along with a pie chart of sigma proportion. The user will provide the individual normalized method decision chart by filling in the test name in the field.



Figure S2 The Summarize sheet and the Westgard sigma rule for QC design and run size.

In the Control level 1 and Control level 2 sheets, the user must input control data to prepare to create Levey-Jennings control charts. In addition, this Excel VBA calculates the cumulative mean, SD and CV. The cumulative CV is a long-term estimate of the central tendency observed for a control material based on a large number of control measurements collected over a long period ( $\geq$  6 months). Comparing the monthly CV to the cumulative CV, if the monthly CV is more than twice the cumulative CV, then it should be investigated and documented. Any significant change may indicate a change in instrument calibration or a fault in its function.

The Bias sheet collects monthly bias data and is convenient for summary and usage. The Corrective Action sheet is a document that collects corrections that solve the error or are out of control from all the operating tests.

-

Cull	nulative	Na	к	CI	CO2	Glucose	Urea	Creatinine	Uric Acid	Cholestero	Triglyceride	HDL	LDL
mean		114.44	3.80	92.86	14.18	101.21	19.83	0.89	5.13	91.55	112.66	27.64	58.28
SD													
cv	%	1.43	1.56	1.23	3.91	1.42	2.31	1.53	1.32	2.52	1.39	3.40	1.80
Bias	%	2.32		2.37	0.00	0.58		2.05	3.08		2.46		
Sigma		2.04	2.43	2.00	1	4.70	3.11	4.10	4.42	2.33	6.58	6.02	7.10
No.	Date	Na_1	K_1	Cl_1	C02_1	Glu_1	BUN_1	Crea_1	UA_1	TC_1			
1	7/3/2023	112.2	3.73	91.1	14.6	100	20.34	0.9	5.17	95	Cont	trol lev	rel 1
2	8/3/2023	114.8	3.81	94.4	14.2	100	19.49	0.87	5.13	90	Con		CC I
3	9/3/2023 10/3/2023	113.4 112.8	3.77 3.75	91.7 91.3	13.9 14.8	101 100	20.43 19.46	0.9	5.12 5.18	96 90	115	26.5	57.3
5	11/3/2023	112.0	3.75	91.3	14.0	100	19.46	0.88	5.16	90	113	26.7	57.5
Cum	ulative	Na	ĸ	CI	C02	Glucose	Ilrea	Creatinine	Uric Acid	Cholesterol	Triglyceride	HDI	LDI
	ulative	Na	K	CI	CO2	Glucose	Urea	Creatinine	Contraction of the other distances of		Triglyceride	HDL	LDL
mean	ulative	137.31	7.00	109.09	23.60	244.96	58.49	3.52	10.80	182.48	210.32	60.41	120.32
mean SD		137.31 2.41	7.00 0.11	109.09 1.38	23.60 1.03	244.96 3.87	58.49 1.32	3.52 0.07	10.80 0.17	182.48 3.17	210.32 3.42	60.41 1.36	120.3 2.47
mean SD CV	wlative %	137.31 2.41 1.76	7.00 0.11 1.62	109.09	23.60	244.96 3.87 1.58	58.49 1.32 2.25	3.52	10.80 0.17 1.58	182.48 3.17 1.74	210.32 3.42 1.62	60.41 1.36 2.25	120.32
mean SD CV	%	137.31 2.41	7.00 0.11	109.09 1.38 1.27	23.60 1.03 4.38	244.96 3.87	58.49 1.32	3.52 0.07 1.95	10.80 0.17	182.48 3.17	210.32 3.42	60.41 1.36	120.32 2.47 2.05
mean SD CV Bias	%	137.31 2.41 1.76 2.32	7.00 0.11 1.62 2.16	109.09 1.38 1.27 2.37	23.60 1.03 4.38	244.96 3.87 1.58 0.58	58.49 1.32 2.25 1.41	3.52 0.07 1.95 2.05	10.80 0.17 1.58 3.08	182.48 3.17 1.74 4.10	210.32 3.42 1.62 2.46	60.41 1.36 2.25 0.41	120.32 2.47 2.05 2.26
mean SD CV Bias	% % Date	137.31 2.41 1.76 2.32 2.04 Na_2	7.00 0.11 1.62 2.16 2.43 K_2	109.09 1.38 1.27 2.37 2.00	23.60 1.03 4.38 0.00	244.96 3.87 1.58 0.58 4.70	58,49 1.32 2.25 1.41 3.11 BUN_2	3.52 0.07 1.95 2.05 4.10	10.80 0.17 1.58 3.08 4.42 UA_2	182.48 3.17 1.74 4.10 2.33 TC_2	210.32 3.42 1.62 2.46	60.41 1.36 2.25 0.41	120.32 2.47 2.05 2.26
mean SD CV Bias Sigma No. 1	9%0 9%0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	137,31 2,41 1,76 2,32 2,04 Na 2 134,3	7.00 0.11 1.62 2.16 2.43 <u>K_2</u> 6.91	109.09 1.38 1.27 2.37 2.00 Cl_2 108.5	23.60 1.03 4.38 0.00 CO2_2 23.5	244.96 3.87 1.58 0.58 4.70	58.49 1.32 2.25 1.41 3.11 BUN_2 58.67	3.52 0.07 1.95 2.05 4.10 Crea 2 3.48	10.80 0.17 1.58 3.08 4.42 UA_2 10.72	182.48 3.17 1.74 4.10 2.33 TC 2 178	210.32 3.42 1.62 2.46 6.58	60.41 1.36 2.25 0.41 6.02	120.3 2.47 2.05 2.26 7.10
mean SD CV Bias Sigma No. 1 2	% % % % % % % % % % % % % % % % % % %	137.31 2.41 1.76 2.32 2.04 Na_2 134.3 136.4	7.00 0.11 1.62 2.16 2.43 K_2 6.91 6.92	109.09 1.38 1.27 2.37 2.00 CL_2 108.5 110.3	23.60 1.03 4.38 0.00 0 0 23.5 22.6	244.96 3.87 1.58 0.58 4.70 Glu_2 240 246	58.49 1.32 2.25 1.41 3.11 BUN_2 58.67 58.81	3.52 0.07 1.95 2.05 4.10 Crea_2 3.48 3.53	10.80 0.17 1.58 3.08 4.42 UA_2 10.72 10.72	182.48 3.17 1.74 4.10 2.33 TC_2 178 182	210.32 3.42 1.62 2.46 6.58	60.41 1.36 2.25 0.41	120.3 2.47 2.05 2.26 7.10
mean SD CV Bias Sigma No. 1	9%0 9%0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	137,31 2,41 1,76 2,32 2,04 Na 2 134,3	7.00 0.11 1.62 2.16 2.43 <u>K_2</u> 6.91	109.09 1.38 1.27 2.37 2.00 Cl_2 108.5	23.60 1.03 4.38 0.00 CO2_2 23.5	244.96 3.87 1.58 0.58 4.70	58.49 1.32 2.25 1.41 3.11 BUN_2 58.67	3.52 0.07 1.95 2.05 4.10 Crea 2 3.48	10.80 0.17 1.58 3.08 4.42 UA_2 10.72	182.48 3.17 1.74 4.10 2.33 TC 2 178	210.32 3.42 1.62 2.46 6.58	60.41 1.36 2.25 0.41 6.02	120.32 2.47 2.05 2.26 7.10

	Bia	_		> September 2023 Tu We Th Fr Sa				Year			Ionth		
	DId:	5	28	29 30 31 1 2 5 6 7 8 9	3			2023			กุมภาพันธ์	มีนาคม	เมษายน
	)	3	11 18	12         13         14         15         16           19         20         21         22         23           26         27         28         29         30	17 24								
				3 4 5 0	0			Bias.	year				
									2023				Bias shoot
test	Date	Hunth	Time	Your value	Assigned value	N.Bas	-	test	2023 กุมภาพันธ์	มีนาคม	เมษายน		Bias sheet
Contractory	Date 28/2/2023	<b>เนาต</b> กุมภาพันธ์	2023			<b>Video</b> 1.51	1.51	<b>test</b> ALB	B CONTRACTOR	<b>มีนาคม</b> 1.19	<b>เมษายน</b> 1.20	1.30	Bias sheet
test ALB ALP			2023 2023	Your value	Assigned value	1.51 5.51	1.51 5.51		กุมภาพันธ์		1000.00000	1.30	Bias sheet

Date	Name	Rules violation	N	Error	Cause	Corrective	Cause event	Error (n)		
Mar 23	from_Amy	13s	2	Random error	Technique	Repeat control	test name	RE	SE	sum
Mar 23	from_P	41s	2	Systemic error	Reagent	Calibrate and Repeat control	from_BUN		4	4
Mar 23	from_Ca	13s	2	Random error	Technique	repeat control traw at 30 min	Control material		2	2
0 Mar 23	from ALP	8x	2	Systemic error	Reagent	Calibrate and Repeat control	Technique		1	1
Mar 23	from_Glu	13s	2	Random error	Technique	repeat control traw at 30 min				
0 Mar 23	from DirectBili	41s	2	Systemic error	Control material	calibrate and repeat control	Correctiv	Action	choo	+
0 Mar 23	from_CRP	8x	2	Systemic error	Reagent	Calibrate and Repeat control	CONECTIV	e Action	1 21166	L
1 Mar 23	from DirectBili	41s	2	Systemic error	Reagent	calibrate and repeat control				

Figure S3 The Control level 1, level 2, Bias and Corrective Action sheet.



Archives of Allied Health Sciences 2024; 36(1): 40-47.

# Least significant change as an essential tool for monitoring of bone mineral density using dual energy X-ray absorptiometry

Thantip Pholwattana<sup>1,\*</sup>, Sirinthorn Sridubdim<sup>2</sup>, Sirinya Nanthanangkul<sup>3</sup>

<sup>1</sup> Department of Nuclear Medicine, Udonthani Cancer Hospital, Udonthani, Thailand.

<sup>2</sup> Department of Radiology, Udonthani Cancer Hospital, Udonthani, Thailand.

<sup>3</sup> Department of Nursing Academic Officer, Udonthani Cancer Hospital, Udonthani, Thailand.

#### **KEYWORDS**

Least significant change; Precision error; Bone mineral density; Dual-energy absorptiometry.

#### ABSTRACT

Dual-energy X-ray absorptiometry (DXA) scans are the gold standard for measuring bone mineral density (BMD). It is accepted that precision error is crucial in monitoring BMD measurements. The least significant change (LSC) signifies the minimum difference between two consecutive BMD measurements that can confidently indicate a genuine biological change. This value provides direct benefit to patients by aiding clinicians in making clinical decisions based on real change or stability of BMD. This study aimed to determine the LSC for DXA scan used at Udonthani Cancer Hospital. We conducted a cross-sectional study in 150 patients undertaking DXA scans performed by one of our five radio-technologists from March 2023 to September 2023. Each technologist assessed BMD study of 30 participants twice, obtaining paired BMD measurements for the lumbar vertebrae, hip, and forearm. We utilized the copy of region of interest (ROI) software to replicate the ROI. The LSC was calculated with a 95% CI using both the RMS SD and RMS %CV formulas. The obtained LSC were 3.26% for the L1-L4 vertebrae, 4.40% for the femoral neck, 2.30% for the total proximal femur, and 5.30% for the 33% radius, meeting 2019 International Society for Clinical Densitometry (ISCD) standards. Nevertheless, the ISCD 2019 guidelines do not provide acceptable value for determining the LSC at the 33% radius. The higher variability in measurements at the femoral neck and the 33% radius emphasizes the need for continuous professional development and enhanced reproducible methods to improve the precision of BMD measurement using DXA scans.

\*Corresponding author: Thantip Pholwattana, MD. Department of Nuclear Medicine, Udonthani Cancer Hospital, Udonthani, Thailand. Email address: thantipnm@gmail.com.

Received: 15 March 2024/ Revised: 25 March 2024/ Accepted: 27 March 2024

### Introduction

Dual-energy X-ray absorptiometry (DXA) scan is the gold standard method for measuring bone mineral density (BMD), playing a vital role in diagnosing osteoporosis, assessing risk of fracture, and monitoring changes in BMD over time<sup>(1-4)</sup>. The core principle of DXA is the measurement of transmission of X-ray with high- and low-energy photons through the body<sup>(2)</sup>. Precision error becomes particularly critical especially in the monitoring of consecutive BMD measurements using DXA<sup>(1)</sup>.

The least significant change (LSC) represents the least amount of BMD change that can be considered statistically significant. In simpler terms, it signifies the minimum difference between two consecutive measurements that can confidently indicate a genuine biological change, exceeding precision error of the method $^{(3,5)}$ . The LSC helps clinicians make clinical decisions based on real change or stability of BMD. Several factors affect this value, including the instrument used, the characteristics of the patient population, the measurement site, and the skill of the radio-technologist in positioning the patient (radio-technologist's precision). Notably, the radio-technologist's precision is the key factor in determining the LSC<sup>(3)</sup>. In addition, although the manufacturer-provided LSC is available in each BMD machine, it cannot be accurately applied and used for different settings due to variable skills of patient positioning by different technologists<sup>(1)</sup>. We aimed to determine the LSC for DXA scan utilized at Udonthani Cancer Hospital.

## Materials and methods

#### Study design and participants

During March 2023 to September 2023, we enrolled new participants referred for DXA scans at Udonthani Cancer Hospital. Inclusion criteria were age  $\geq$  18 years with good cooperation, whereas exclusion criteria included pregnant

women, individuals with disabilities, and those exceeding 159 kg in body weight which is over the machine capacity. Ethical approval for the study was obtained from the local Ethics Committee, and informed written consent was obtained from all participants.

A cross-sectional study was conducted using DXA scan (Lunar Prodigy, GE) to analyze bone mineral density results from 150 participants, with examinations performed by five radiotechnologists. Following the 2019 International Society for Clinical Densitometry (ISCD) guidelines<sup>(6)</sup>, each radio-technologist assessed 30 participants twice. Prior to undergoing a second DXA scan, participants were asked to step down from the densitometer and then be repositioned. Paired measurements of BMD were acquired for the lumbar vertebrae, hip, and forearm<sup>(6)</sup>. In addition, we utilized the copy of region of interest (ROI) software to replicate the ROI from the initial set of images to the subsequent set. The ROIs are shown in figure S1 (supplement data).

We assessed the individual LSC at L1-L4 vertebrae, femoral neck, total proximal femur, and 33% radius for each radio-technologist, as well as our institute LSC. The LSC was calculated with a 95% confidence interval (95% CI) using both the root mean square standard deviation (RMS SD) and root mean square percentage coefficient of variation (RMS %CV) formulas<sup>(6)</sup>.

#### Research protocol

Participant data, including age, sex, ethnicity, menopausal status, body weight, height, BMI, underlying diseases, and current medications were collected. The characteristics of all participants are summarized in table 1. Table 2 classifies the characteristics of the groups studied by each individual radiotechnologist. Table 3 presents details about the radio-technologists, such as their age, duration of experience with DXA, and the number of prior DXA cases before their participation in this study.

#### Statistical analysis

Continuous variables such as age, weight, height, and BMI were shown as mean  $\pm$  SD and median (min-max). Categorical variables such as gender, ethnicity, menopausal status, underlying diseases, and current medications were demonstrated in both numbers and percentages. The RMS SD, RMS%CV, and LSC at the 95% confidence interval were computed employing the ISCD Advanced Precision Calculating Tool<sup>(7)</sup>. This calculator expresses precision error as RMS SD (absolute value in g/cm<sup>2</sup>), CV or %CV and LSC with a range of confidence levels. It is exclusively indicated for advanced bone densitometrists and should be used in particular clinical practice scenarios or clinical research.

## Results

Among the 150 participants, ranging from 20 to 87 years of age, with the mean age of 52.5 years, the majority, 80.7%, were female. Menopausal status was reported in 67.8% of the female participants, while male accounted for 19.3% of the total. More than half of the participants, 96 cases (64%), had underlying diseases, predominantly thyroid cancer and breast cancer, undergoing thyroid hormone suppression, and aromatase inhibitor treatments, respectively. The remaining participants were healthy, as detailed in table 1.

	Table 1	Participant	characteristics
--	---------	-------------	-----------------

Variable	Value
Age: years	
Mean ± SD	52.5±11.5
Median (min-max)	52.0 (20.0-87.0)
Sex: (n, %)	
Male	29.0 (19.3)
Female	121.0 (80.7)
Menopausal status (n, %)	
Premenopausal	39.0 (32.3)
Menopausal	82.0 (67.8)
Ethnics (n, %)	
Thai	150.0 (100.0)
BMI: kg/m²	
Mean ± SD	24.5±4.0
Median (min-max)	23.9 (17.3-37.6)
< 18.5 (Underweight)	8.0 (5.3)
18.5 - 24.9 (Normal weight)	80.0 (53.3)
25.0 - 29.9 (Pre-obesity)	47.0 (31.3)
30.0 - 34.9 (Obesity class I)	13.0 (8.7)
35.0 - 39.9 (Obesity class II)	2.0 (1.3)
$\geq$ 40.0 (Obesity class III)	-

Variable	Value
Underlying disease (n, %)	
Healthy	54.0 (36.0)
Thyroid cancer	50.0 (33.3)
Breast cancer	23.0 (15.3)
Hyperthyroidism	3.0 (2.0)
Hyperparathyroidism	2.0 (1.4)
Others	18.0 (12.0)
Current medication (n, %)	
No medication	54.0 (36.0)
Thyroid hormone	50.0 (33.3)
Aromatase inhibitor	16.0 (10.7)
Others	30.0 (20.0)

#### Table 1 Participant characteristics (Cont.)

Abbreviation: SD, standard deviation; BMI, Body mass index.

Table 2 illustrates participant characteristics divided into five groups by each radio-technologist.

Baseline clinical and demographic characteristics were well balanced among the groups.

Variable		I	Radio-technolog	ist	
Variable	Α	В	С	D	E
Age (years)					
Mean ± SD	50.2±14.8	52.9±9.6	49.0±9.2	54.3±10.5	55.9±12.1
Median	47.5	52.0	50.0	55.5	55.0
(min-max)	(28.0-87.0)	(34.0-71.0)	(20.0-64.0)	(32.0-85.0)	(23.0-85.0)
Sex:					
Female (n, %)	24.0 (19.8)	22.0 (18.2)	30.0 (24.8)	26.0 (21.5)	19.0 (15.7)
Weight (kg)					
Mean ± SD	59.6±14.2	66.1±11	60.4±12.7	61.3±11.1	60.1±9.8
Median	57.3	66.8	55.1	60.0	59.0
(min-max)	(40.0-96.0)	(44.6-87.0)	(39.5-98.6)	(42.0-87.0)	(42.3-78.0)
Height (cm)					
Mean ± SD	157.4±6.8	160.1±9.2	157.3±5.6	157.2±7.8	160.0±7.2
Median	155.0	158.5	157.0	156.0	160.0
(min-max)	(148.0-175.0)	(143.0-179.0)	(147.0-170.0)	(139.0-174.0)	(145.0-174.0)

 Table 2
 Participant characteristics divided by each radio-technologist (A, B, C, D, E)

Variable	Radio-technologist									
Variable	Α	В	С	D	E					
BMI (kg/m <sup>2</sup> )										
Mean ± SD	23.9±4.8	25.8±3.5	24.3±4.7	24.8±3.9	23.3±2.7					
Median	22.8	25.5	23.1	24.2	23.6					
(min-max)	(17.3-35.2)	(19.1-32.7)	(18.3-37.6)	(17.9-32.1)	(17.8-29.1)					

Table 2 Participant characteristics divided by each radio-technologist (A, B, C, D, E) (Cont.)

Abbreviation: SD, standard deviation; BMI, Body mass index.

The characteristics of each radio-technologist are displayed in table 3. The duration of their work experience with DXA ranges from two to three years. Radio-technologist A has the most experience, with 178 previous DXA cases, while radio-technologist C has the lowest, with 62 previous cases.

Table 3	Characteristics	of radio-technologists	(A, B, C, D, E)
---------	-----------------	------------------------	-----------------

Variable						
	Α	В	С	D	Е	- Mean
Age: years	40	52	48	46	56	48.4
Duration of work experience with DXA scan: years	3	3	2	2	2	2.4
Number of previous DXA cases	178	97	62	63	69	93.8

Abbreviation: DXA, Dual-energy X-ray absorptiometry.

#### Table 4 The LSC by RMS%CV formula

	LSC (%)							
Α	В	С	D	Е	Average			
3.57	3.14	3.21	3.58	2.80	3.26			
4.91	2.93	5.71	4.07	4.37	4.40			
2.06	1.62	2.80	2.21	2.81	2.30			
4.96	1.62	6.40	4.78	8.75	5.30			
	4.91 2.06	3.573.144.912.932.061.62	A         B         C           3.57         3.14         3.21           4.91         2.93         5.71           2.06         1.62         2.80	A         B         C         D           3.57         3.14         3.21         3.58           4.91         2.93         5.71         4.07           2.06         1.62         2.80         2.21	A         B         C         D         E           3.57         3.14         3.21         3.58         2.80           4.91         2.93         5.71         4.07         4.37           2.06         1.62         2.80         2.21         2.81			

Abbreviation: LSC, Least significant change; RMS%CV, root mean square percentage coefficient of variation.

Site		LSC (g/cm <sup>2</sup> )						
	Α	В	С	D	Е	Average		
L1-L4 vertebrae	0.037	0.034	0.037	0.038	0.032	0.036		
Femoral neck	0.050	0.026	0.054	0.035	0.034	0.040		
Total proximal femur	0.018	0.015	0.028	0.019	0.025	0.021		
33% Radius	0.041	0.015	0.052	0.037	0.066	0.042		

#### Table 5 The LSC by RMS SD formula

Abbreviation: LSC, Least significant change; RMS SD, root mean square standard deviation.

## Discussion

The LSC determined using the RMS%CV formula were as follows: 3.26% for the L1-L4 vertebrae, 4.40% for the femoral neck, 2.30% for the total proximal femur, and 5.30% for the 33% radius. Notably, each of these values falls within the acceptable thresholds established by the ISCD 2019 guidelines, which specifies 5.3% for the L1-L4 vertebrae, 6.9% for the femoral neck, and 5.0% for the total proximal femur<sup>(6)</sup>. However, there are no standard criteria for the 33% radius as this site is not typically included in the routine DXA scan.

A peer review by Wilson et al<sup>(8)</sup> reported the LSC of 1.22% at the L1-L4 vertebrae and 1.97% at the femoral neck<sup>(8)</sup>, which were lower than those observed for both L1-L4 vertebrae and femoral neck in our study. Moreover, apart from the total proximal femur, the LSC values for nearly all sites in our study were higher than those reported by Nelson et al<sup>(9)</sup>. The LSC values they provided for the L1-L4 vertebrae, the femoral neck, and the total proximal femur were 0.028, 0.030, and 0.021 g/cm<sup>2</sup>, respectively<sup>(9)</sup>. Even though Nelson et al<sup>(9)</sup> analyzed LSC results from eight radio-technologists, which potentially caused larger variability, their LSC results were still better than those observed in our study. This might be due to the relatively less experience of our radio-technologists.

Additionally, the LSC for nearly all sites in our study were higher than those recommended by the manufacturer which specify LSC values of 0.010, 0.014, 0.012, and  $0.020 \text{ g/cm}^2$  for the L1-L4 vertebrae, the femoral neck, the total proximal femur, and the 33% radius, respectively. However, there is no disclosure of the sources of the process in obtaining these numbers.

# Conclusion

This study determined the LSC among five radio-technologists, with half of participants were cancer patients. The results showed that the LSC values across various sites —specifically the L1-L4 vertebrae, the femoral neck, and the total proximal femur—met ISCD standards. Nevertheless, the ISCD 2019 guidelines do not provide acceptable criteria for determining the LSC at the 33% radius. The higher variability in measurements at the femoral neck and the 33% radius emphasizes the need for ongoing professional development through re-training to improve reproducibility and enhance the precision of BMD measurements using DXA.

## Take home messages

Although ISCD 2019 recommends that individual institutions ascertain their own LSC, some face limitations due to the need for sufficient volunteers and additional time required for repeat scans. Therefore, LSC in this study may be a reference standard for institutions sharing patient demographics, numbers, and levels of experience among radio-technologists.

# **Conflicts of interest**

The authors declare no conflict of interest.

## **Acknowledgements**


The authors gratefully thank all the participants in this study for their kind cooperation.

## References

- Baim S, Wilson CR, Lewiecki EM, Luckey MM, Downs Jr RW, Lentle BC. Precision assessment and radiation safety for dual-energy X-ray absorptiometry: position paper of the International Society for Clinical Densitometry. J Clin Densitom 2005; 8(4): 371-8.
- Crabtree NJ, Leonard MB, Zemel BS. Dual-energy X-ray absorptiometry. In: Sawyer AJ, Bachrach LK, Fung EB, editors. Bone densitometry in growing patients: guidelines for clinical practice. Totowa: Humana Press; 2007. p. 41-57.

- 3. Kim HS, Yang SO. Quality control of DXA system and precision test of radio-technologists. J Bone Metab 2014; 21(1): 2-7.
- 4. Najm N, Popp C, Traylor D, Jesch E. Least Significant Change of Body Composition and Bone Mineral Density Measured by Dual energy X-Ray Absorptiometry. FASEB J 2015; 29(S1): 632-8.
- Jaworski M, Pludowski P. Precision errors, least significant change, and monitoring time interval in pediatric measurements of bone mineral density, body composition, and mechanostat parameters by GE lunar prodigy. J Clin Densitom 2013; 16(4): 562-9.
- Shuhart CR, Yeap SS, Anderson PA, Jankowski LG, Lewiecki EM, Morse LR, et al. Executive summary of the 2019 ISCD position development conference on monitoring treatment, DXA cross-calibration and least significant change, spinal cord injury, peri-prosthetic and orthopedic bone health, transgender medicine, and pediatrics. J Clin Densitom 2019; 22(4): 453-71.

- International Society for Clinical Densitometry. Precision calculation tool [online] 1993 [cited 2023 Dec 28]. Available from: https://iscd. org/learn/resources/calculators/advancedcalculator/
- Wilson KE, Smith AP. Monitoring BMD with DXA: Short- and Long-term Precision [online] 2009 [cited 2019 Oct 21]. Available from: https:// hologiced.com/wp-content/uploads/ 2018/06/Wilson-KE-and-Smith-AP.-Monitoring-BMD-with-DXA-W-157.pdf.
- Nelson L, Gulenchyn KY, Atthey M, Webber CE. Is a fixed value for the least significant change appropriate? J Clin Densitom 2010; 13(1): 18-23.



# Supplementary

Figure S1 The ROIs include (A) L1-L4 vertebrae, (B) femoral neck and total proximal femur, and (C) 33% radius.

Abbreviation: ROIs, Region of interest.